Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry. This journal is © The Royal Society of Chemistry 2022

Electronic Supplementary Information (ESI)

## Structure-Activity Relationship and Bioactivity Studies of Neurotrophic *trans*-Banglene

Khyati Gohil<sup>a</sup>, M. Zain H. Kazmi<sup>a</sup>, Florence J. Williams<sup>b\*</sup>

<sup>a</sup> University of Alberta, Edmonton, Alberta, Canada <sup>b</sup> University of Iowa, Iowa City, Iowa, USA <u>florence-williams@uiowa.edu</u>

# **Table of Contents**

| 1. | General Information         | <b>S03</b> |
|----|-----------------------------|------------|
| 2. | General Procedures          | <b>S04</b> |
| 3. | Optical Purity Data         | S22        |
| 4. | PC-12 Cell Assay Procedures | S39        |
| 5. | References                  | S43        |

### **General Information**

All reactions were performed under a nitrogen atmosphere unless stated otherwise. Dichloromethane  $(CH_2Cl_2)$  and toluene were passed through a column of activated molecular sieves (4Å, LC technologies SP-1 solvent purification system). HPLC purification was performed using an Agilent 1260 preparatory system, using one of the following: a C8 Zorbax column (PrepHT, 21.2x150mm, 7 µm particle size), Lux® 5 µm i-Amylose-3 column (250 x 10 mm, 5 µm particle size) or Daicel CHIRALPAK AD-H (250 x 30 mm). Chiral HPLC analysis was performed using a normal-phase Agilent 1260 system, with UV detection using a standard diode-array- detector, and one of the following: a Daicel CHIRALPAK IG column (150 x 4.6 mm, 5 µm particle size), IC Daicel CHIRALPAK IC column (150 x 4.6 mm, 5 µm particle size), or a Daicel CHIRALPAK AD-H (250 x 4.6 mm).

NMR spectra were obtained from one of the following Varian spectrometers: DD2 MR 400MHz, VNMRS 500MHz, VNMRS 600MHz, VNMRS 700MHz. NMR spectra chemical shifts ( $\delta$ ) are reported in ppm and are referenced to residual protonated solvent (<sup>1</sup>H) or deuterated solvent (<sup>13</sup>C) chemical shifts. Coupling constants (*J*) are reported in Hertz (Hz). The following abbreviations are used: s = singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublets, dq = doublet of quartets, ddd = doublet of doublet of doublets, tdd = triplet of doublet of doublets, m = multiplet, app. = apparent, br. = broad. HSQC was used to determine <sup>13</sup>C NMR multiplicities, which are reported as follows: C = no attached hydrogens, CH = one attached hydrogen, CH<sub>2</sub> = two attached hydrogens, CH<sub>3</sub> = three attached hydrogens.

HRMS were obtained from a Kratos Analytical MS50G EI-MS. FTIR were obtained using a Thermo Nicolet 8700 with an attached continuum microscope. Optical rotation data was obtained using a Perkin Elmer 241 Polarimeter at 589 nm at 25 °C, using a 10 cm path-length cell.

#### **General Procedures**

Synthesis of allyl alcohols  $(2a-d)^{1}$ 



1a-d

2a-d

The aldehyde **1** (30 mmol) was dissolved in tetrahydrofuran (25 mL). Allyl bromide (8 mL, 90 mmol) and saturated aqueous NH<sub>4</sub>Cl solution (125 mL) were then added, and the reaction mixture was cooled to 0 °C. Zinc power (12 g, 180 mmol) was added, and the reaction mixture was stirred at 0 °C for 30 minutes. The precipitate was filtered, and the filtrate was extracted with ethyl acetate (25 mLx4). The organic layers were combined and washed with brine (25 mLx1), then dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and then concentrated in vacuo. The resulting product was used without further purification.

**2a.** 1-(3,4-Dimethoxyphenyl)but-3-en-1-ol: White solid (91%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$ : 6.94–6.83 (m, 3H), 5.85–5.76 (m,1H), 5.20–5.14 (m, 2H), 4.70 (td, J = 6.5 Hz, 3.0 Hz, 1H), 3.90 (s, 3H), 3.88 (s, 3H), 2.51 (t, J = 6.9 Hz, 2H), 1.96 (d, J = 3.0 Hz, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 176 MHz)  $\delta$ : 149.1, 148.2, 134.6, 118.4, 118.1, 111.0, 109.0, 73.3, 56.0, 55.9, 43.9. Characterization data is consistent with literature.<sup>2</sup>

**2b. 1-(3-Methoxyphenyl)but-3-en-1-ol:** Yellow oil (99%). <sup>1</sup>**H NMR** (CDCl<sub>3</sub>, 400 MHz) δ: 7.29–7.25 (t, *J* = 8.0, 1H), 6.95–6.93 (m, 2H), 6.82 (ddd, *J* = 8.4 Hz, 2.6 Hz, 1.2 Hz, 1H), 5.87–5.77 (m, 1H), 5.20–5.14 (m, 1H), 4.73 (dd, *J* = 7.7 Hz, 4.2 Hz, 1H), 3.82 (s, 3H), 2.56–2.45 (m, 2H), 2.03 (s, 1H). <sup>13</sup>**C NMR** (CDCl<sub>3</sub>, 176 MHz) δ: 159.8, 145.7, 134.5, 129.5, 118.5, 118.2, 113.1, 111.4, 73.3, 55.3, 43.9. Characterization data is consistent with literature.<sup>3</sup>

**2c. 1-(4-Methoxyphenyl)but-3-en-1-ol:** Yellow oil (99%). <sup>1</sup>**H NMR** (CDCl<sub>3</sub>, 700 MHz) δ: 7.29–7.28 (app. d, *J* = 8.3 Hz, 2H), 6.89–6.88 (app. d, *J* = 8.7 Hz, 2H), 5.83–5.77 (m, 1H), 5.17–5.12 (m, 2H), 4.70 (t, *J* = 6.5 Hz, 1H), 3.81 (s, 3H), 2.52–2.49 (app. t, *J* = 6.5 Hz, 2H), 1.94 (s, 1H). <sup>13</sup>**C NMR** (CDCl<sub>3</sub>, 176 MHz) δ: 159.0, 136.0, 134.6, 127.0, 118.2, 113.8, 72.9, 55.3, 43.7. Characterization data is consistent with literature.<sup>3</sup>

**2d. 1-(3-hydroxy-4-methoxy)but-3-en-1-ol:** Colourless oil (99%). <sup>1</sup>**H-NMR** (CDCl<sub>3</sub>, 600 MHz) δ: 6.93–6.82 (m, 3H), 5.84–5.78 (m, 1H), 5.58 (s, 1H), 5.19–5.13 (m, 2H), 4.69–4.66 (td, *J* = 4.8 Hz, 3.0 Hz, 1H), 3.91 (s, 3H), 2.51–2.49 (m, 2H), 1.99 (d, *J* = 3.0 Hz, 1H). <sup>13</sup>**C NMR** (CDCl<sub>3</sub>, 125 MHz) δ: 146.6, 145.1, 136.0, 134.6, 118.9, 118.3, 114.1, 108.3, 73.3, 55.9, 43.9. Characterization data is consistent with literature.<sup>1</sup> (*this compound decomposes at room temperature*).

Synthesis of dienes  $(3a \text{ and } 3c)^{1}$ 



In a flame dried RBF, the alcohol **2** (14 mmol) was dissolved in toluene (40 mL). N,Ndiisopropylethylamine (72 mmol) and methanesulfonyl chloride (22 mmol) were slowly added and the reaction mixture was heated at reflux for 1 hour. The mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub>(45 mL), washed with sodium bicarbonate (15 mLx3), water (15 mLx3), and brine (15 mLx2). Then the organic layer dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and then concentrated in vacuo. The resultant oil was purified by column chromatography (silica; isocratic: 8% ethyl acetate/hexane).

**3a. 4-((***E***)-Buta-1,3-dienyl)-1,2-dimethoxybenzene:** Yellow oil (45%). R<sub>f</sub> = 0.1. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz) δ: 6.97–6.94 (m, 2H), 6.82 (d, *J* = 8.2 Hz, 1H), 6.67 (dd, *J* = 15.4 Hz, 10.6 Hz, 1H), 6.53–6.45 (m, 2H), 5.29 (d, *J* = 16.7 Hz, 1H), 5.13 (d, *J* = 10.0 Hz, 1H), 3.91 (s, 3H), 3.89 (s, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 126 MHz) δ: 149.1, 148.9, 137.3, 132.7, 130.3, 128.0, 119.9, 116.7, 111.2, 108.7, 60.0, 55.9. Characterization data are consistent with literature.<sup>4</sup>

**3c.** (*E*)-1-(buta-1,3-dien-1-yl)-4-methoxybenzene: Yellow oil (45%).  $R_f = 0.3$ . <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$ : 7.34 (d, *J* = 8.7 Hz, 2H), 6.86 (d, *J* = 8.8 Hz, 2H), 6.67 (dd, *J* = 15.6 Hz, 10.5 Hz, 1H), 6.53–6.45 (m, 2H), 5.28 (d, *J* = 16.9 Hz, 1H), 5.11 (d, *J* = 10.1 Hz, 1H), 3.81 (s, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 176 MHz)  $\delta$ : 159.3, 137.4, 132.4, 129.9, 127.6, 116.4, 114.1, 55.3. Characterization data are consistent with literature.<sup>5</sup>

#### Synthesis of 3b: (E)-1-(buta-1,3-dien-1-yl)-3-methoxybenzene

In a flame dried RBF, 1-(3 methoxy)-but-3-en-1-ol (**2b**, 170 mg, 1.0 mmol) was dissolved in 4 mL toluene, followed by the addition of 3Å molecular sieves. Pyridine (0.6 mL, 7.0 mmol) and phosphoryl chloride (0.16 mL, 2.10 mmol) were slowly added, and the reaction mixture was heated at reflux overnight. The reaction mixture was diluted with  $CH_2Cl_2$  (15 mL), washed with 0.01 M HCl (5 mLx2), NaHCO<sub>3</sub> (sat. aq.)(5 mLx1), water (5 mLx2), and brine (10 mLx1). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> filtered, and then concentrated in vacuo. The resultant oil was purified with column chromatography (silica; isocratic: 15% ethyl acetate/hexane,  $R_f = 0.3$ ) to remove residual starting alcohol, and the yellow oil (107 mg, 70% 3b) was then carried forward to synthesise 20 and 22.

### Synthesis of 3d: (E)-4-(Buta-1, 3-dienyl)-2-methoxyphenol

In a flame dried RBF, alcohol **2d** (4.50 mmol) was dissolved in toluene (40.0 mL), followed by the addition of p-toluenesulphonic acid (0.09 mmol). The reaction mixture was then heated at reflux for 50 mins. The reaction solution was washed with aq. sat. sodium bicarbonate (10 mLx2), brine (10 mL) and then the organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The resulting residue was purified by column chromatography (silica; 5-10 % ethyl acetate/hexane,  $R_f = 0.4$  in 10% ethyl acetate/hexane).

Low melting white solid (12%). <sup>1</sup>**H NMR** (CDCl<sub>3</sub>, 400 MHz,): 6.94–6.88 (m, 3H), 6.70–6.64 (m, 1H), 6.55–6.46 (m, 2H), 5.77 (s, 1H), 5.31 (dd, J = 17.6 Hz, 1.6 Hz, 1H), 5.14 (dd, J = 10.0 Hz, 2.0 Hz, 1H), 3.90 (s, 3H). <sup>13</sup>**C NMR** (CDCl<sub>3</sub>, 125 MHz)  $\delta$ : 146.8, 145.7, 137.4, 132.9, 129.9, 127.6, 120.5, 116.5, 114.7, 108.4, 55.9. Characterization data are consistent with literature.<sup>1</sup>

Synthesis of Banglenes (c–BG, t–BG) and homo-dimeric Banglene derivatives (20-23)<sup>6</sup>



In a flame dried RBF, the corresponding diene (0.62 mmol) was dissolved in toluene (2 mL). Hydroquinone (0.12 mmol) was added only for synthesis of (**20-23**), and the reaction was allowed to stir at reflux, for 18 hours. Toluene was removed in vacuo, and the resulting residue was purified by column chromatography (silica). The cis/trans diastereomers were then separated by preparative HPLC.

| n vo d v ot | silica column     | product              | HPLC separation               | HPLC      | isolated components |        |                      |  |
|-------------|-------------------|----------------------|-------------------------------|-----------|---------------------|--------|----------------------|--|
| product     | conditions        | (% yield) conditions |                               | injection |                     | amount | R <sub>t</sub> (min) |  |
| c–BG        | 20% EtOAc/hex     | 390 mg               | C8 column. 50→100%            | 250 mg    | t–BG                | 164 mg | 10.8                 |  |
| t-BG        | $R_{\rm f} = 0.3$ | (40%)                | ACN/H <sub>2</sub> O (20 min) | 550 mg    | с-BG                | 166 mg | 11.3                 |  |
| 20          | 20% EtOAc/hex     | 90 mg                | i-amylose-3 column.           | 70        | 20                  | 10 mg  | 9.4                  |  |
| 22          | $R_f = 0.4$       | (90%)                | 97% hex/EtOH (15 min)         | 70 mg     | 22                  | 5 mg   | 8.6                  |  |
| 21          | 5% EtOAc/hex      | 47 mg                | i-amylose-3 column.           | 40        | (-) 21              | 5 mg   | 14.5                 |  |
| 23          | $R_{\rm f} = 0.2$ | (47%)                | 97% hex/EtOH (15 min)         | 40 mg     | (+) 23              | 4 mg   | 11.3                 |  |

#### (±) 3(*S*/*R*)-(3,4-Dimethoxyphenyl)-4(*S*/*R*)-[(*E*)-3,4-dimethoxystyryl]cyclohex-1-ene (*c*-BG):

Colourless oil. <sup>1</sup>**H NMR** (CDCl<sub>3</sub>, 700MHz)  $\delta$  : 6.79 (d, J = 8.2 Hz, 1H), 6.75–6.72 (m, 4H), 6.69 (d, J =

1.9 Hz, 1H), 6.24 (d, J = 15.8 Hz, 1H), 5.97 (tdd, J = 2.3 Hz, 4.4 Hz, 10.0 Hz, 1H), 5.79 (tdd, J = 2.3 Hz, 4.4 Hz, 10 Hz, 1H), 5.58 (dd, J = 9.2 Hz, 15.8 Hz), 3.85 (s, 3H), 3.84 (s, 3H), 3.82 (s, 3H), 3.74 (s, 3H), 3.50 (br. s, 1H), 2.70 (dddd, J = 3.1 Hz, 5.5 Hz, 9.1 Hz, 10.9 Hz, 1H), 2.27–2.16 (m, 2H), 1.68–1.59 (m, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 176 MHz)  $\delta$ : 149.0, 148.3, 148.2, 147.6, 133.9, 132.5, 131.1, 129.2, 128.6, 128.1, 122.0, 118.8, 113.7, 111.2, 110.4, 108.8, 56.0, 55.9, 55.8, 45.8, 42.7, 24.9, 24.4. Characterization data are consistent with literature.<sup>7</sup>

(±) 3(S/R)-(3,4-Dimethoxyphenyl)-4(R/S)-[(E)-3,4-dimethoxystyryl]cyclohex-1-ene (t-BG): Yellow oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 700MHz)  $\delta$ : 6.82 (d, J = 1.8 Hz, 1H), 6.8 (dd, J = 1.9 Hz, 8.3 Hz, 1H), 6.77 (t, J = 7.8 Hz, 2H), 6.72 (dd, J = 1.9 Hz, 8.2 Hz, 1H), 6.7 (d, J = 1.9 Hz, 1H), 6.09 (d, J = 15.9 Hz, 1H), 6.02 (dd, J = 7.6 Hz, 15.9 Hz), 5.90 (tdd, J = 2.5 Hz, 4.3 Hz, 10.0 Hz, 1H), 5.68 (dq, J = 10.2 Hz, 2.2 Hz, 1H), 3.87 (s, 3H), 3.86 (s, 3H), 3.85 (s, 3H), 3.82 (s, 3H), 3.18 (dq, J = 8.6 Hz, 2.8 Hz), 2.36 (dq, J = 9.0 Hz, 2.8 Hz 1H), 2.24–2.20 (m, 2H), 1.92 (dq, J = 13.3 Hz, 4.1 Hz), 1.70–1.65 (m, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 176 MHz)  $\delta$ : 149.0, 148.6, 148.3, 147.4, 137.6, 132.2, 131.0, 130.3, 128.9, 127.6, 120.5, 118.8, 111.7, 111.2, 110.9, 108.8, 55.98, 55.92, 55.89, 55.88 48.1, 45.5, 27.9, 24.2. Characterization data are consistent with literature.<sup>7</sup>

(±) 3(*S/R*)-(3-methoxyphenyl)-4(*R/S*)-[(*E*)-3-methoxystyryl]cyclohex-1-ene (20): Yellow oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600MHz) δ: 7.18 (q, *J* = 7.7 Hz, 2H), 6.86 (d, *J* = 7.7 Hz, 1H), 6.80–6.78 (m, 2H), 6.74–6.72 (m, 3H), 6.17–6.16 (m, 2H), 5.90 (tdd, *J* = 2.4 Hz, 4.4 Hz, 10 Hz, 1H), 5.70 (dq, *J* = 10.0 Hz, 2.2 Hz, 1H), 3.79 (s, 3H), 3.77 (s, 3H), 3.23 (dq, *J* = 11.0 Hz, 2.7 Hz, 1H), 2.45–2.41 (1.0 Hz, 2H), 2.26–2.19 (m, 2H), 1.92 (tdd, *J* = 3.2 Hz, 5.2 Hz, 12.6 Hz, 1H), 1.70–1.64 (m, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 176 MHz) δ: 159.8 (C), 159.6 (C), 146.6 (C), 139.4 (C), 134.4 (CH), 129.9 (CH), 129.4 (CH), 129.2 (CH), 129.1 (CH), 127.6 (CH), 121.1 (CH), 118.7 (CH), 114.2 (CH), 112.4 (CH), 111.5 (CH), 111.5 (CH), 55.2 (CH<sub>3</sub>), 55.2 (CH<sub>3</sub>), 48.4 (CH), 45.2 (CH), 27.8 (CH<sub>2</sub>), 24.5 (CH<sub>2</sub>). **HRMS** (EI, C<sub>22</sub>H<sub>24</sub>O<sub>2</sub>, M<sup>+</sup>): calcd.: 320.1776, found: 320.1782. **FTIR** (cast film): 3021, 2928, 2834, 1599, 1488, 1264, 1156, 1050, 777 cm<sup>-1</sup>.

(-) 3(*R*)-(4-methoxyphenyl)-4(*S*)-[(*E*)-4-methoxystyryl]cyclohex-1-ene (21): Yellow oil. [α]<sup>25</sup><sub>D</sub> –237 (*c* = 0.7, CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 700MHz) δ: 7.19 (d, *J* = 8.7 Hz, 2H), 7.10 (d, *J* = 8.6 Hz, 2H), 6.82–6.80 (m, 4H), 6.11 (d, *J* = 15.9 Hz, 2H), 6.02 (dd, *J* = 7.6 Hz, 15.9 Hz, 1H), 5.88 (tdd, *J* = 2.5 Hz, 4.2 Hz, 10.0 Hz, 1H), 5.65 (dq, *J* = 9.8 Hz, 2.2 Hz, 1H), 3.78 (s, 3H), 3.78 (s, 3H), 3.18 (dq, *J* = 11.0 Hz, 2.7 Hz 1H), 2.35 (dq, *J* = 2.7 Hz, 8.9 Hz, 1H), 2.23–2.18 (m, 2H), 1.91 (dq, *J* = 12.5 Hz, 4.2 Hz, 1H), 1.68–1.63 (m, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 176 MHz) δ: 158.7 (C), 158.0 (C), 137.2 (C), 132.1 (C), 130.8 (CH), 130.5 (CH), 129.4 (CH), 128.5 (CH), 127.4 (CH), 127.1 (CH), 113.9 (CH), 113.6 (CH), 55.3 (CH<sub>3</sub>), 55.3 (CH<sub>3</sub>), 47.7 (CH), 45.5 (CH), 27.9 (CH<sub>2</sub>), 24.6 (CH<sub>2</sub>). FTIR (cast film): 3020, 2927, 2835, 1609, 1511, 1249,

1175, 1037 cm<sup>-1</sup>. **HRMS** (EI, C<sub>22</sub>H<sub>24</sub>O<sub>2</sub>, M<sup>+</sup>): calcd.: 320.1776, found: 320.1774. **FTIR** (cast film): 3018, 2929, 2835, 1609, 1511, 1249, 1176, 1037 cm<sup>-1</sup>.

(±) 3(S/R)-(3-methoxyphenyl)-4(S/R)-[(*E*)-3-methoxystyryl]cyclohex-1-ene (22): Colourless oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 700MHz) δ: 7.20–7.17 (m, 1H), 7.15 (t, *J* = 7.9 Hz, 1H), 6.79 (dd, *J* = 7.5 Hz, 13.2 Hz, 2H), 6.67–6.75 (m, 2H), 6.73–6.71 (m, 2H), 6.27 (d, *J* = 15.8 Hz, 1H), 5.98 (tdd, *J* = 2.4 Hz, 3.4 Hz, 10.1 Hz, 1H), 5.82–5.76 (m, 2H), 3.77 (s, 3H), 3.74 (s, 3H), 3.57 (br. s, 1H), 2.76 (dddd, *J* = 3.1 Hz, 5.6 Hz, 9.1 Hz, 10.4 Hz, 1H), 2.28–2.17 (m, 2H), 1.74–1.64 (m, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 176 MHz) δ 159.7 (C), 159.2 (C), 143.1 (C), 139.5 (C), 134.3 (CH), 129.4 (CH), 129.0 (CH), 128.9 (CH), 128.5 (CH), 128.2 (CH), 122.6 (CH), 118.8 (CH), 115.8 (CH), 112.5 (CH), 111.7 (CH), 111.4 (CH), 55.2 (CH<sub>3</sub>), 46.0 (CH), 42.5 (CH), 24.6 (CH<sub>2</sub>), 24.6 (CH<sub>2</sub>). **HRMS** (EI, C<sub>22</sub>H<sub>24</sub>O<sub>2</sub>, M<sup>+</sup>): calcd.: 320.1776, found: 320.1775. **FTIR** (cast film): 3021, 2926, 2835, 1599, 1486, 1264, 1155, 1049, 776 cm<sup>-1</sup>.

(+) 3(*S*)-(4-methoxyphenyl)-4(*R*)-[(*E*)-4-methoxystyryl]cyclohex-1-ene (23): Colorless oil.  $[\alpha]^{25}_{D}$ +212 (*c* = 0.6, CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 700MHz)  $\delta$ : 7.14 (d, *J* = 8.6 Hz, 1H), 7.10 (d, *J* = 8.6 Hz, 1H), 6.82 (d, *J* = 8.7 Hz, 2H), 6.79 (d, *J* = 8.8 Hz, 2H), 6.25 (d, *J* = 15.9 Hz, 1H), 5.95 (tdd, *J* = 2.4 Hz, 3.8 Hz, 10.0 Hz, 1H), 5.8 (tdd, *J* = 2.2 Hz, 4.5 Hz, 10.0 Hz, 1H), 5.60 (dd, *J* = 9.1 Hz, 15.9 Hz, 1H), 3.79 (s, 3H), 3.78 (s, 3H), 3.52 (br. s, 1H), 2.70 (dddd, *J* = 3.3 Hz, 5.5 Hz, 9.0 Hz, 10.5 Hz, 1H), 2.27–2.14 (m, 2H), 1.68–1.58 (m, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 176 MHz)  $\delta$ : 158.7 (C), 158.1 (C), 133.4 (C), 132.1 (C), 131.0 (CH), 130.9 (CH), 129.4 (CH), 128.4 (CH), 127.9 (CH), 127.1 (CH), 113.9 (CH), 113.1 (CH), 55.3 (CH<sub>3</sub>), 55.3 (CH<sub>3</sub>), 43.3 (CH), 42.8 (CH), 24.8 (CH<sub>2</sub>), 24.4 (CH<sub>2</sub>). **HRMS** (EI, C<sub>22</sub>H<sub>24</sub>O<sub>2</sub>, M<sup>+</sup>): calcd.: 320.1776, found: 320.1775. **FTIR** (cast film): 3018, 2929, 2835, 1609, 1511, 1249, 1176, 1037 cm<sup>-1</sup>.

Synthesis of cis-aldehydes  $(5a-d)^{1}$ 



In a flame dried RBF, the corresponding diene (4 mmol) was dissolved in  $CH_2Cl_2$  (12 mL) and cooled to -78 °C. Acrolein (6 mmol) was added, followed by the dropwise addition of  $Et_2AlCl$  (3.8 mmol). The reaction mixture was stirred at -78 °C for 10 minutes and then warmed to 0 °C. The reaction was quenched with 1N HCl (15 mL) and extracted with  $CH_2Cl_2$  (20 mLx2). The combined organic layers were washed with NaHCO<sub>3</sub>(sat. aq.) (15 mLx2), then brine(10mLx1), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and then

concentrated in vacuo. The crude residue was purified with column chromatography (silica; isocratic: 20 % ethyl acetate/hexane).

(±) (1*S*, 2*R*)-2-(3,4-Dimethoxyphenyl)cyclohex-3-ene-1-carboxyaldehyde (5a): White semi-solid (46%).  $R_f = 0.36$ . <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz)  $\delta$ : 9.50 (d, *J* = 2.1 Hz, 1H), 6.80 (d, *J* = 8.2 Hz, 1H), 6.76 (dd, *J* = 8.2 Hz, 2.1 Hz, 1H), 6.72 (d, *J* = 1.9 Hz, 1H), 5.99–5.97 (m, 1H), 5.83–5.80 (m, 1H), 3.93–3.91 (m,1H), 3.85 (s, 6H), 2.76–2.72 (m, 1H), 2.32–2.26 (m, 1H), 2.19–2.12 (m, 1H), 1.88–1.85 (m, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 126 MHz)  $\delta$ : 205.0, 148.8, 148.1, 132.6, 128.5, 128.1, 121.4, 112.6, 111.1, 55.9, 50.9, 41.2, 23.7, 18.9. Characterization data are consistent with literature.<sup>7</sup>

(±) (1*S*, 2*R*)-2-(3-Dimethoxyphenyl)cyclohex-3-ene-1-carboxyaldehyde (5b): Yellow oil (22%),  $R_f = 0.6. {}^{1}H NMR (CDCl_3, 500MHz) \delta$ : 9.51 (d, *J* = 2.1 Hz, 1H), 7.23–7.20 (m, 1H), 6.81 (d, *J* = 7.7 Hz, 1H), 6.77–6.76 (m, 2H), 6.00–5.97 (m, 1H), 5.84–5.81 (m,1H), 3.95–3.94 (m, 1H), 3.79 (s, 3H), 2.77–2.74 (m, 1H), 2.30–2.26 (m, 1H), 2.18–2.12 (m, 1H), 1.92–1.85 (m, 2H). {}^{13}C NMR (CDCl\_3, 126MHz) \delta: 204.7 (CH), 159.7 (C) ,141.8 (C), 129.4 (CH), 128.8 (CH), 127.8 (CH), 121.7 (CH), 115.5 (CH), 112.0 (CH), 55.2 (CH<sub>3</sub>), 50.7 (CH), 41.5 (CH), 23.6 (CH<sub>2</sub>), 19.0 (CH<sub>2</sub>). HRMS (EI, C<sub>14</sub>H<sub>16</sub>O<sub>2</sub>, M<sup>+</sup>): calcd.: 216.1150, found: 216.1148.

**(±)** (1*S*, 2*R*)-2-(4-Dimethoxyphenyl)cyclohex-3-ene-1-carboxyaldehyde (5c). Yellow oil (44%). R<sub>f</sub> = 0.3. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 700MHz) δ: 9.51 (d, *J* = 1.9 Hz, 1H), 7.13 (d, *J* = 8.6 Hz, 2H), 6.83 (d, *J* = 8.7 Hz, 2H), 5.98–5.96 (m, 1H), 5.80 (m, 1H), 3.95–3.92 (m, 1H), 3.78 (s, 3H), 2.75–2.72 (m, 1H), 2.31–2.25 (m, 1H), 2.18–2.11 (m,1H), 1.89–1.80 (m, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 126MHz) δ: 158.7, 132.1, 130.3, 128.4, 128.2, 113.8, 112.9, 55.3, 51.0, 40.8, 23.7, 18.6. HRMS (EI, C<sub>14</sub>H<sub>16</sub>O<sub>2</sub>, M<sup>+</sup>): calcd.: 216.1150, found: 216.1153.

(±) (1*S*, 2*R*)-2-(4-hydroxy-3-methoxyphenyl)-cyclohex-3-ene-1-carboxaldehyde (5d): Yellow oil (30%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ: 9.49 (d, *J* = 2 Hz, 1H), 6.82 (d, *J* = 8.4 Hz, 1H), 6.72–6.68 (m, 2H), 5.98–5.93 (m, 1H), 5.81–5.77 (m, 1H), 5.65 (br. s, 1H), 3.91–3.87 (m, 1H), 3.83 (s, 3H), 2.74–2.69 (m, 1H), 2.30–2.24 (m, 1H), 2.17–2.12 (m, 1H), 1.87–1.81 (m, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz) δ: 205.2, 146.5, 144.7, 131.9, 128.5, 128.2, 122.1, 114.4, 111.9, 55.9, 50.9, 41.2, 23.6, 18.8. Characterization data are consistent with literature.<sup>1</sup>

Racemization of cis-aldehydes to trans-aldehydes  $(6a-c)^7$ 



The corresponding *cis*-aldehyde **5** (1.4 mmol) was dissolved in methanol (15 mL), followed by the addition of  $K_2CO_3$  (1.6 mmol). The reaction solution was stirred at room temperature for 48 hours. The reaction mixture was diluted with  $CH_2Cl_2$  (20 mL) and washed with water (10 mL) and brine (10 mL). The organic layer was dried over  $Na_2SO_4$  and concentrated in vacuo.

(±) (1*R*, 2*R*)-2-(3,4-Dimethoxyphenyl)cyclohex-3-ene-1-carboxyaldehyde (6a): Yellow oil (85%, 87:13 6a:5a). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz) δ: 9.69 (d, *J* = 1.5 Hz, 1H), 6.81–6.72 (m, 3H), 5.92 (dq, *J* = 10.0 Hz, 3.3 Hz, 1H), 5.70 (dq, *J* = 2.5 Hz, 10.0 Hz, 1H), 3.86 (d, *J* = 5.6 Hz, 6H), 3.76–3.72 (m, 1H), 2.60 (dddd, *J* = 1.6 Hz, 3.5 Hz, 7.6 Hz, 9.4 Hz, 1H), 2.23–2.18 (m, 2H), 2.01–1.95 (m, 1H), 1.81–1.74 (m, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 126 MHz) δ: 205.0, 148.8, 148.1, 132.6, 128.5, 128.1, 121.4, 112.6, 111.1, 55.9, 50.9, 41.2, 23.7, 18.9. Characterization data are consistent with literature.<sup>7</sup>

(±) (1*R*, 2*R*)-2-(3-Dimethoxyphenyl)cyclohex-3-ene-1-carboxyaldehyde (6b): Yellow oil (71%, 90:10 6b:5b). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500MHz) δ: 9.70 (d, *J* = 1.3 Hz, 1H), 7.23 (t, *J* = 7.8 Hz, 1H), 6.83 (d, *J* = 7.7 Hz, 1H), 6.79–6.75 (m, 2H), 5.90 (dq, *J* = 9.5Hz, 3.3 Hz, 1H), 5.68 (dq, *J* = 10.0 Hz, 2.4 Hz, 1H), 3.80 (s, 3H), 3.77–3.73 (m, 1H), 2.61 (ddt, *J* = 1.3 Hz, 3.5 Hz, 8.5 Hz, 1H), 2.20–2.15 (m, 2H), 2.0–1.93 (m, 1H), 1.80–1.72 (m,1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 126MHz) δ: 203.8 (CH), 159.8 (C), 145.3 (C), 129.6 (CH), 128.7 (CH), 127.8 (CH), 120.7 (CH), 114.2 (CH), 111.9 (CH), 55.3 (CH<sub>3</sub>), 53.9 (CH), 41.4 (CH), 23.5 (CH<sub>2</sub>), 20.9 (CH<sub>2</sub>). **HRMS** (EI, C<sub>14</sub>H<sub>16</sub>O<sub>2</sub>, M<sup>+</sup>): calcd.: 216.1150, found: 216.1150.

(±) (1*R*, 2*R*)-2-(4-Dimethoxyphenyl)cyclohex-3-ene-1-carboxyaldehyde (6c): Yellow oil (87%, 90:10 6c:5c). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500MHz)  $\delta$ : 9.69 (d, *J* = 1.2 Hz, 1H), 7.15 (d, *J* = 8.5 Hz, 2H), 6.85 (d, *J* = 8.6 Hz, 2H), 5.88 (dq, *J* = 9.5 Hz, 3.3 Hz, 1H), 5.66 (dq, *J* = 9.5 Hz, 2.4 Hz, 1H), 3.79 (s, 3H), 3.74–3.70 (m, 1H), 2.56 (ddt, *J* = 1.5 Hz, 4.3 Hz, 8.5 Hz, 1H), 2.21–2.15 (m, 2H), 1.95 (dq, 1H, *J* = 13.5 Hz, 4.3 Hz), 1.78-1.71 (m,1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 126MHz)  $\delta$ : 204.0 (CH), 158.4 (C) ,135.6 (C), 129.3 (CH<sub>2</sub>), 129.2 (CH<sub>2</sub>), 127.5 (CH), 114.0 (CH), 55.3 (CH<sub>3</sub>), 54.2 (CH), 40.7 (CH<sub>2</sub>), 23.5 (CH<sub>2</sub>), 21.0 (CH<sub>2</sub>). HRMS (EI, C<sub>14</sub>H<sub>16</sub>O<sub>2</sub>, M<sup>+</sup>): calcd.: 216.1150, found: 216.1148.

### Synthesis of Wittig Salts (7a-f)

In a flame dried RBF, the corresponding bromide (5.4 mmol) was dissolved in toluene (20 mL), followed by addition of triphenylphosphine (5.4 mmol). The reaction solution was then heated at reflux overnight. The organic layer was concentrated in vacuo to afford a crude white solid which was then purified by recrystallization in ethanol (7a), or ethanol/diethyl ether (7b-f).

**3,4-Methoxybenzyltriphenylphosphonium bromide (7a)**: White powder (61%). <sup>1</sup>**H** NMR (CDCl<sub>3</sub>, 400MHz)  $\delta$ : 7.78–7.74 (m, 9H), 7.65–7.62 (m, 6H), 6.86 (s, 1H), 6.62–6.61 (m, 2H), 5.37 (d, *J* = 13.8 Hz, 2H), 3.80 (s, 3H), 3.55 (s, 3H). <sup>13</sup>**C** NMR (CDCl<sub>3</sub>, 126MHz)  $\delta$ : 148.9, 148.8, 134.8 (d, *J* = 3.1 Hz), 134.6 (d, *J* = 9.5 Hz), 130.0 (d, *J* = 12.6 Hz), 123.7 (d, *J* = 6.2 Hz), 119.0 (d, *J* = 9.0 Hz), 118.3, 117.8, 115.0, (d, *J* = 4.8 Hz), 111.0 (d, *J* = 3.4 Hz), 56.1, 55.80, 30.5, 30.2. <sup>31</sup>P{<sup>1</sup>H} NMR (CDCl<sub>3</sub>, 201.64 MHz)  $\delta$ : 22.5 (s). Characterization data is consistent with literature.<sup>8</sup>

**Benzyltriphenylphosphonium bromide (7b):** White powder (76%). <sup>1</sup>**H NMR** (CDCl<sub>3</sub>, 400MHz)  $\delta$ : 7.78–7.72 (m, 9H), 7.65–7.60 (td, J = 7.8 Hz, 3.6 Hz, 6H), 7.23–7.19 (m, 1H), 7.14–7.09 (m, 4H), 5.43 (d, J = 14.4 Hz, 2H). <sup>13</sup>**C NMR** (CDCl<sub>3</sub>, 176 MHz)  $\delta$ : 135.0 (d, J = 3.1 Hz), 134.5 (d, J = 9.8 Hz), 131.6 (d, J = 5.6 Hz), 130.2 (d, J = 12.3 Hz), 128.9 (d, J = 3.4 Hz), 128.4 (d, J = 3.9 Hz), 127.2 (d, J = 8.7 Hz), 118.0 (d, J = 85.6 Hz), 31.0 (d, J = 46.6 Hz). <sup>31</sup>**P**{<sup>1</sup>**H**} NMR (CDCl<sub>3</sub>, 162 MHz)  $\delta$ : 23.2 (s). Characterization data is consistent with literature.<sup>9</sup>

**3-Methoxybenzyltriphenylphosphonium bromide** (**7c**): White powder (65%). <sup>1</sup>**H** NMR (CDCl<sub>3</sub>, 400MHz)  $\delta$ : 7.78–7.73 (m, 9H), 7.63 (td, *J* = 7.7 Hz, 3.4 Hz, 6H), 7.02 (t, *J* = 8.0 Hz, 1H), 6.82 (q, *J* = 1.8 Hz, 1H), 6.76 (dt, *J* = 8.2 Hz, 2.1 Hz, 1H), 6.63 (d, *J* = 7.5, 1H), 5.40 (d, *J* = 14.4 Hz, 2H), 3.55 (s, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 176 MHz)  $\delta$ : 159.7, 135.0 (d, *J* = 3.1 Hz), 134.6 (d, *J* = 9.8 Hz), 130.1 (d, *J* = 12.6 Hz), 129.7 (d, *J* = 3.1 Hz), 123. 5 (d, *J* = 5.9 Hz), 118.2, 117.7, 116.3 (d, *J* = 5.3 Hz), 115.4 (d, *J* = 3.9 Hz), 55.5, 31.9 (d, *J* = 46.8 Hz). <sup>31</sup>P{<sup>1</sup>H} NMR (CDCl<sub>3</sub>, 161.913 MHz)  $\delta$ : 23.23 (s). Characterization data is consistent with literature.<sup>10</sup>

**4-Methoxybenzyltriphenylphosphonium bromide** (**7d**): White powder (65%). <sup>1</sup>**H** NMR (CDCl<sub>3</sub>, 400MHz)  $\delta$ : 7.77–7.71 (m, 9H), 7.64–7.61 (m, 6H), 7.03 (dd, J = 2.5 Hz, 8.8 Hz, 2H), 6.65 (d, J = 8.6 Hz, 2H), 5.35 (dd, J = 3.2 Hz, 14.0 Hz, 2H), 3.72 (s, 3H). <sup>13</sup>**C** NMR (CDCl<sub>3</sub>, 176 MHz)  $\delta$ : 159.7, 134.9 (d, J = 3.1 Hz), 134.5 (d, J = 9.5 Hz), 132.8 (d, J = 5.3 Hz), 130.2 (d, J = 12.6 Hz), 118.3, 117.8, 114.3 (d, J = 3.1 Hz), 55.3, 30.2 (d, J = 46.6 Hz). <sup>31</sup>**P**{<sup>1</sup>**H**} NMR (CDCl<sub>3</sub>, 161.913 MHz)  $\delta$ : 22.4 (s). Characterization data is consistent with literature.<sup>11</sup>

**2-Methylbenzyltriphenylphosphonium bromide (7e):** White powder (71%). <sup>1</sup>**H** NMR (CDCl<sub>3</sub>, 400MHz)  $\delta$ : 7.81–7.76 (m, 3H), 7.72–7.61 (m, 12H), 7.15 (t, *J* = 7.3 Hz, 1H), 7.09 (d, *J* = 7.2 Hz, 1H), 7.0–6.96 (m, 2H), 5.37 (d, *J* = 14.1 Hz, 2H), 1.68 (s, 3H). <sup>13</sup>**C** NMR (CDCl<sub>3</sub>, 176 MHz)  $\delta$ : 138.6, 135.1 (d, *J* = 2.8 Hz), 134.4 (d, *J* = 9.8 Hz), 131.6, 131.0, 130.22 (d, *J* = 12.6 Hz), 128.8, 126.7, 125.7, 122.0, 118.2, 117.8, 28.5 (d, *J* = 46.6 Hz). <sup>31</sup>**P**{<sup>1</sup>**H**} NMR (CDCl<sub>3</sub>, 161.913 MHz)  $\delta$ : 22.2 (s). Characterization data is consistent with literature.<sup>12</sup>

**2-Bromobenzyltriphenylphosphonium bromide** (**7f**): White powder (87%). <sup>1</sup>**H NMR** (CDCl<sub>3</sub>, 400MHz) δ: 7.81–7.77 (m, 3H), 7.75–7.70 (m, 6H), 7.66–7.59 (m, 7H), 7.37 (d, *J* = 7.9 Hz, 1H), 7.20 (t, *J* = 7.5 Hz, 1H), 7.13 (tt, *J* = 7.7 Hz, 2.0 Hz, 1H), 5.75 (d, *J* = 14.3 Hz, 2H). <sup>13</sup>**C NMR** (CDCl<sub>3</sub>, 126 MHz) δ: 135.2 (d, *J* = 2.8 Hz), 134.5 (d, *J* = 9.8 Hz), 133.5 (d, *J* = 4.9 Hz), 132.9, 130.2 (d, *J* = 12.6 Hz), 128.5 (d, *J* = 3.6 Hz), 118.0, 117.3, 31.1 (d, *J* = 48.2 Hz). Characterization data is consistent with literature.<sup>13</sup>

#### Synthesis of Banglenes and Derivatives (8-19) via a Wittig reaction<sup>1</sup>



In a flame dried RBF, the corresponding Wittig salt **7** (0.6 mmol) was dissolved in toluene (5 mL) and tetrahydrofuran (5 mL) and cooled to -70 °C. n-Butyl lithium (0.73 mmol) was added slowly, and the reaction mixture was allowed to stir at -70 °C for 1 hour. The reaction solution was then warmed up to  $-20^{\circ}$  C, the corresponding aldehyde (**6**) was added, and the reaction was then heated at reflux for 3 hours. The reaction mixture was quenched with saturated aqueous NH<sub>4</sub>Cl (5 mL), and then concentrated in vacuo. The crude oil was dissolved in ethyl acetate (30 mL), washed with water (10 mLx2), and NaHCO<sub>3</sub> (sat. aq.) (10 mLx2), was dried over Na<sub>2</sub>SO<sub>4</sub> and then concentrated in vacuo. The resulting oil was purified with column chromatography.

|         | silica column        | product           | separation method     | HPLC      | isol   |          |                      |      |
|---------|----------------------|-------------------|-----------------------|-----------|--------|----------|----------------------|------|
| product | conditions           | mass<br>(% yield) |                       | injection |        | amount   | R <sub>t</sub> (min) | ee   |
|         |                      |                   |                       |           | (+) 8E | 10 mg    | 5.8                  | 99%  |
| 8E      | 20% EtOAc/hex        | 93 mg             | i-amylose-3 column.   | 80        | (-) 8E | 19 mg    | 8.0                  | >99% |
| 8Z      | $R_{\mathrm{f}}=0.4$ | (48%)             | 97% hex/EtOH (15 min) | 80 mg     | (+) 8Z | not      | 5.5                  | -    |
|         |                      |                   |                       |           | (-) 8Z | isolated | 7.2                  | -    |

(±) 3(*S*/*R*)-(3,4-dimethoxyphenyl)-4(*R*/*S*)-[(*E*)-styryl]cyclohex-1-ene (8):

<sup>1</sup>**H NMR** (CDCl<sub>3</sub>, 500MHz)  $\delta$ : 7.26–7.25 (m, 4H, *overlaps with* CDCl<sub>3</sub>), 7.16 (m, 1H), 6.78 (d, J = 8.2 Hz, 1H), 6.72 (dd, J = 2.0 Hz, 8.1 Hz, 1H), 6.70 (d, J = 1.9 Hz, 1H), 6.16 (d, J = 3.3 Hz, 2H), 5.90 (tdd, J = 2.4 Hz, 4.1 Hz, 10.0 Hz, 1H), 5.68 (dq, J = 10.0 Hz, 2.2 Hz, 1H), 3.85 (s, 3H), 3.82 (s, 3H), 3.78 (s, 3H), 3.19 (dq, J = 11.2 Hz, 2.7 Hz, 1H), 2.41–2.35 (m, 1H), 2.27–2.17 (m, 2H), 1.95–1.91 (m, 1H), 1.72–1.64 (m, 1H). <sup>13</sup>**C NMR** (CDCl<sub>3</sub>, 126 MHz)  $\delta$ : 148.6 (C), 147.4 (C), 137.8 (C), 137.5 (C), 134.1 (CH), 130.3 (CH), 129.3 (CH), 128.5 (CH), 127.6 (CH), 126.9 (CH), 126.0 (2xCH), 120.4 (CH), 111.7 (CH), 110.9 (CH), 55.9 (CH<sub>3</sub>), 55.9 (CH<sub>3</sub>), 48.0 (CH), 45.5 (CH), 27.8 (CH<sub>2</sub>), 24.6 (CH<sub>2</sub>).

(+) **8E:** White oil;  $[\alpha]^{25}_{D}$  +296 (*c* = 0.10, CH<sub>2</sub>Cl<sub>2</sub>). **HRMS** (EI, C<sub>22</sub>H2<sub>4</sub>O<sub>2</sub>, M<sup>+</sup>): calcd.: 320.1776, found: 320.1771. **FTIR** (cast film): 3022, 2929, 2835, 1516, 1261, 1139, 1030 cm<sup>-1</sup>.

(-) **8E:** White oil;  $[\alpha]^{25}_{D}$  –290 (c = 0.99, CH<sub>2</sub>Cl<sub>2</sub>). **HRMS** (EI, C<sub>22</sub>H2<sub>4</sub>O<sub>2</sub>, M<sup>+</sup>): calcd.: 320.1776, found: 320.1774. **FTIR** (cast film): 3022, 2929, 2835, 15116, 1261, 1139, 1030 cm<sup>-1</sup>.

|         | silica column     | product<br>mass<br>(% yield) | separation method     | HPLC      | isola   |        |                      |      |
|---------|-------------------|------------------------------|-----------------------|-----------|---------|--------|----------------------|------|
| product | conditions        |                              |                       | injection |         | amount | R <sub>t</sub> (min) | ee   |
|         |                   |                              |                       |           | (+)9E   | 13 mg  | 5.8                  | 99%  |
| 9E      | 15% EtOAc/hex     | 123 mg                       | i-amylose-3 column.   | 110       | (-) 9E  | 25 mg  | 7.8                  | >99% |
| 14Z     | $R_{\rm f} = 0.3$ | (58%)                        | 95% hex/EtOH (15 min) | 110 mg    | (+) 14Z | 9 mg   | 5.2                  | >99% |
|         |                   |                              |                       |           | (-) 14Z | 9 mg   | 6.3                  | >99% |

(±) 3(S/R)-(3,4-dimethoxyphenyl)-4(R/S)-[(E)-3-methoxystyryl]cyclohex-1-ene (9):

<sup>1</sup>**H NMR** (CDCl<sub>3</sub>, 700MHz) δ: 7.17 (t, J = 7.9 Hz, 1H), 6.87 (bd, J = 7.7 Hz, 1H), 6.80 (t, J = 2.0 Hz, 1H), 6.78 (d, J = 8.2 Hz, 1H), 6.74–6.72 (m, 2H), 6.80 (d, J = 1.9 Hz, 1H), 6.18–6.12 (m, 2H), 5.90 (tdd, J = 2.4 Hz, 4.4 Hz, 10.0 Hz, 1H), 5.68 (dq, J = 10.0 Hz, 2.2 Hz, 1H), 3.85 (s, 3H), 3.83 (s, 3H), 3.79 (s, 3H), 3.19 (dq, J = 11.0 Hz, 2.7 Hz, 1H), 2.40–2.36 (m, 1H), 2.28–2.18 (m, 2H), 1.93 (tdd, J = 3.1 Hz, 5.2 Hz, 12.8 Hz 1H), 1.71–1.65 (m, 1H). <sup>13</sup>**C NMR** (CDCl<sub>3</sub>, 176 MHz) δ: 159.8 (C), 148.7 (C), 147.4 (C), 139.3 (C), 137.5 (C), 134.5 (CH), 130.3 (CH), 129.4 (CH), 129.2 (CH), 127.6 (CH), 120.4 (CH), 118.7 (CH),

112.4 (CH), 111.7 (CH), 111.5 (CH), 110.9 (CH), 55.9 (CH<sub>3</sub>), 55.9 (CH<sub>3</sub>), 55.2 (CH<sub>3</sub>), 48.0 (CH), 45.5 (CH), 27.8 (CH<sub>2</sub>), 24.5 (CH<sub>2</sub>).

(+) **9:** White oil;  $[\alpha]^{25}_{D}$  +300 (c = 1.00, CH<sub>2</sub>Cl<sub>2</sub>). **HRMS** (EI, C<sub>23</sub>H<sub>26</sub>O<sub>3</sub>, M<sup>+</sup>): calcd.: 350.1882, found: 350.1878. **FTIR** (cast film): 3018, 2931, 2835, 1598, 1515, 1464, 1261, 1155, 1030 cm<sup>-1</sup>.

(-) **9:** White oil;  $[\alpha]^{25}_{D}$  -294 (*c* = 1.00, CH<sub>2</sub>Cl<sub>2</sub>). **HRMS** (EI, C<sub>23</sub>H<sub>26</sub>O<sub>3</sub>, M<sup>+</sup>): calcd.: 350.1882, found: 350.1875. **FTIR** (cast film): 3019, 2931, 2835, 1598, 1515, 1464, 1261, 1155, 1030 cm<sup>-1</sup>.

**(±)** 3(*S/R*)-(3,4-dimethoxyphenyl)-4(*R/S*)-[(*Z*)-3-methoxystyryl]cyclohex-1-ene (14): <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500MHz) δ: 7.10 (t, *J* = 7.9 Hz, 1H), 6.73 (d, *J* = 8.2 Hz, 1H), 6.69 (dd, *J* = 2.2 Hz, 8.2 Hz, 1H), 6.64 (dd, *J* = 2.0 Hz, 8.2 Hz, 1H), 6.54 (d, *J* = 2.0 Hz, 1H), 6.45 (br. d, *J* = 7.6 Hz, 1H), 6.42 (br. s, 1H), 6.31 (d, *J* = 11.7 Hz, 1H), 5.83 (tdd, *J* = 2.4 Hz, 4.3 Hz, 10 Hz, 1H), 5.64 (dq, *J* = 10.0 Hz, 2.2 Hz, 1H), 5.56 (dd, *J* = 10.5 Hz, 11.6 Hz, 1H), 3.83 (s, 3H), 3.72 (s, 3H), 3.72 (s, 3H), 3.14 (dq, *J* = 11.2 Hz, 2.8 Hz, 1H), 2.85 (dq, *J* = 2.5 Hz, 10.0 Hz, 1H), 2.23–2.12 (m, 2H), 1.82 (tdd, *J* = 3.1 Hz, 5.2 Hz, 13.0 Hz, 1H), 1.67–1.59 (m, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 126 MHz) δ: 159.3 (C), 148.8 (C), 147.4 (C), 139.1 (C), 137.3 (C), 136.9 (CH), 130.4 (CH), 128.8 (CH), 128.8 (CH), 127.3 (CH), 120.9 (CH), 120.4 (CH), 113.9 (CH), 111.9 (CH), 111.2 (CH), 110.8 (CH), 55.9 (CH3), 55.7 (CH<sub>3</sub>), 55.1 (CH<sub>3</sub>), 48.1 (CH), 40.6 (CH), 28.5 (CH<sub>2</sub>), 24.3 (CH<sub>2</sub>).

(+) **14:** White solid;  $[\alpha]^{25}_{D}$  +23 (c = 0.85, CH<sub>2</sub>Cl<sub>2</sub>). **HRMS** (EI, C<sub>23</sub>H<sub>26</sub>O<sub>3</sub>, M<sup>+</sup>): calcd.: 350.1882, found: 350.1876. **FTIR** (cast film): 3000, 2930, 2834, 1576, 1515, 1464, 1260, 1140, 1030 cm<sup>-1</sup>.

(-) **14:** White solid;  $[\alpha]^{25}_{D} - 12$  (c = 0.78, CH<sub>2</sub>Cl<sub>2</sub>). **HRMS** (EI, C<sub>23</sub>H<sub>26</sub>O<sub>3</sub>, M<sup>+</sup>): calcd.: 350.1882, found: 350.1882. **FTIR** (cast film): 2999, 2931, 2834, 1577, 1515, 1464, 1260, 1140, 1030 cm<sup>-1</sup>.

| n vo du at | silica column<br>conditions         | product         | separation method                               | HPLC      |         | 00    |                       |                       |      |
|------------|-------------------------------------|-----------------|---|-----------|---------|-------|-----------------------|-----------------------|------|
| product    |                                     | (% yield)       |   | injection |         | mass  | R <sub>ta</sub> (min) | R <sub>tb</sub> (min) | ee   |
|            |                                     |                 | sequential runs:                                |           | (+) 10E | 13 mg | 16.3                  | 10.6                  | >99% |
| 10E<br>15Z | 20% EtOAc/hex $R_{\rm f} = 0.4$ (4) | 100 mg<br>(48%) | i-amylose-3 column.<br>a. 95% hex/EtOH (30 min) | 90 mg     | (-) 10E | 20 mg | 20.1                  | -                     | 99%  |
|            |                                     |                 |   |           | (+)15Z  | 9 mg  | 16.3                  | 11.9                  | 98%  |
|            |                                     |                 | b. 97% hex/EtOH (20 min)                        |           | (-) 15Z | 109mg | 16.3                  | 9.3                   | 99%  |

(±) 3(S/R)-(3,4-dimethoxyphenyl)-4(R/S)-[(E)-4-methoxystyryl]cyclohex-1-ene (10):

<sup>1</sup>**H NMR** (CDCl<sub>3</sub>, 700MHz)  $\delta$ : 7.20 (d, *J* = 8.7 Hz, 2H), 6.79 (dd, *J* = 17.0 Hz, 8.5 Hz, 3H), 6.72 (dd, *J* = 1.8 Hz, 8.1 Hz, 1H), 6.70 (d, *J* = 1.8 Hz, 1H), 6.11 (d, *J* = 15.9 Hz, 1H), 6.02 (dd, 7.5 Hz, 15.9 Hz, 1H), 5.89 (tdd, *J* = 2.5 Hz, 4.5 Hz, 10.0 Hz, 1H), 5.68 (dq, *J* = 9.8 Hz, 2.3 Hz, 1H), 3.86 (s, 3H), 3.82 (s, 3H), 3.79 (s, 3H), 3.17 (dq, *J* = 11.2 Hz, 2.8 Hz, 1H), 2.35 (dq, *J* = 2.6 Hz, 8.9 Hz, 1H), 2.24–2.18 (m, 2H), 1.92 (tdd, *J* = 3.1 Hz, 5.3 Hz, 12.8 Hz, 1H), 1.69–1.64 (m, 1H). <sup>13</sup>**C NMR** (CDCl<sub>3</sub>, 176 MHz)  $\delta$ : 158.7

(C), 148.6 (C), 147.4 (C), 137.7 (C), 132.0 (C), 130.7 (CH), 130.4 (CH), 128.6 (CH), 127.6 (CH), 127.1 (2 CH), 120.4 (CH), 113.9 (2 CH), 111.8 (CH), 110.9 (CH), 55.9 (CH<sub>3</sub>), 55.9 (CH<sub>3</sub>), 55.3 (CH<sub>3</sub>), 48.1 (CH), 45.4 (CH), 27.9 (CH<sub>2</sub>), 24.6 (CH<sub>2</sub>).

(+) **10:** White oil;  $[\alpha]^{25}_{D}$  +335 (c = 1.00, CH<sub>2</sub>Cl<sub>2</sub>). **HRMS** (EI, C<sub>23</sub>H<sub>26</sub>O<sub>3</sub>, M<sup>+</sup>): calcd.: 350.1882, found: 350.1875. **FTIR** (cast film): 3018, 2931, 2835, 1607, 1512, 1250, 1139, 1031 cm<sup>-1</sup>.

(-) **10:** White oil;  $[\alpha]^{25}_{D}$  -303 (c = 1.00, CH<sub>2</sub>Cl<sub>2</sub>). **HRMS** (EI, C<sub>23</sub>H<sub>26</sub>O<sub>3</sub>, M<sup>+</sup>): 350.1882, found: 350.1879. **FTIR** (cast film): 3018, 2931, 2835, 1607, 1512, 1250, 1139, 1031 cm<sup>-1</sup>.

**(±)** 3(*S/R*)-(3,4-dimethoxyphenyl)-4(*R/S*)-[(*Z*)-4-methoxystyryl]cyclohex-1-ene (15): <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500MHz) δ: 6.78 (d, *J* = 8.6 Hz, 2H), 6.73 (t, *J* = 5.5 Hz, 3H), 6.66 (dd, *J* = 2.0 Hz, 8.2 Hz, 1H), 6.55 (d, *J* = 1.9 Hz, 1H), 6.27 (d, *J* = 11.7 Hz, 1H), 5.84 (tdd, *J* = 2.4 Hz, 4.3 Hz, 10.0 Hz, 1H), 5.65 (dq, *J* = 10.0 Hz, 2.2 Hz, 1H), 5.49 (dd, *J* = 10.4 Hz, 11.6 Hz, 1H), 3.84 (s, 3H), 3.77 (s, 3H), 3.72 (s, 3H), 3.14 (dq, *J* = 11.1 Hz, 2.8 Hz, 1H), 2.81 (dq, *J* = 2.3 Hz, 10.0 Hz, 1H), 2.23–2.12 (m, 2H), 1.82 (tdd, *J* = 3.1 Hz, 5.3 Hz, 13.0 Hz, 1H), 1.67–1.59 (m, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 126 MHz) δ: 158.1(C), 148.8 (C), 147.4 (C), 137.4 (C), 135.5 (CH), 130.4 (CH), 130.3 (C), 129.5 (CH), 128.3 (CH), 127.4 (CH), 120.5 (CH), 113.3 (CH), 111.3 (CH), 110.8 (CH), 56.0 (CH<sub>3</sub>), 55.7 (CH<sub>3</sub>), 55.2 (CH<sub>3</sub>), 48.1 (CH), 40.5 (CH), 28.4 (CH<sub>2</sub>), 24.4 (CH<sub>2</sub>).

(+) **15:** White solid;  $[\alpha]^{25}_{D}$  +16 (c = 1.10, CH<sub>2</sub>Cl<sub>2</sub>). **HRMS** (EI, C<sub>23</sub>H<sub>26</sub>O<sub>3</sub>, M<sup>+</sup>): calcd.: 350.1882, found: 350.1876. **FTIR** (cast film): 350.1882, found: 350.1878. **FTIR** (cast film): 2999, 2929, 2835, 1607, 1512, 1249, 1139, 1031 cm<sup>-1</sup>.

(-) **15:** White solid;  $[\alpha]^{25}_{D} - 8$  (c = 1.10, CH<sub>2</sub>Cl<sub>2</sub>). **HRMS** (EI, C<sub>23</sub>H<sub>26</sub>O<sub>3</sub>, M<sup>+</sup>): 350.1882, found: 350.1878. **FTIR** (cast film): 2999, 2929, 2835, 1607, 1512, 1249, 1139, 1031 cm<sup>-1</sup>.

| n vo d v ot | silica column        | product   | separation method     | HPLC      | isola   |        |                      |     |
|-------------|----------------------|-----------|-----------------------|-----------|---------|--------|----------------------|-----|
| product     | conditions           | (% yield) |                       | injection |         | amount | R <sub>t</sub> (min) | ee  |
|             |                      |           |                       |           | (+)11E  | 20 mg  | 10.7                 | 98% |
| 11E         | 20% EtOAc/hex        | 141 mg    | i-amylose-3 column.   | 140       | (-) 11E | 24 mg  | 12.6                 | 99% |
| 16Z         | $R_{\mathrm{f}}=0.4$ | (70%)     | 97% hex/EtOH (20 min) | 140 mg    | (+) 16Z | 20 mg  | 9.7                  | 99% |
|             |                      |           |                       |           | (-) 16Z | 19 mg  | 11.7                 | 99% |

(±) 3(*S*/*R*)-(3,4-dimethoxyphenyl)-4(*R*/*S*)-[(*E*)-2-methylstyryl]cyclohex-1-ene (11):

<sup>1</sup>**H NMR** (CDCl<sub>3</sub>, 700MHz) δ: 7.33 (d, *J* = 8.4 Hz, 1H), 7.12–7.07 (m, 3H), 6.78 (d, *J* = 8.2 Hz, 1H), 6.73 (dd, *J* = 8.4 Hz, 2.0 Hz, 1H), 6.71 (d, *J* = 2.1 Hz, 1H), 6.31 (d, *J* = 15.7 Hz, 1H), 5.98 (dd, *J* = 7.9 Hz, 15.9 Hz, 1H), 5.89 (tdd, *J* = 2.5 Hz, 4.6 Hz, 2.5 Hz, 1H), 5.69 (dq, 10.1 Hz, 2.2 Hz, 1H), 3.85 (s, 3H), 3.84 (s, 3H), 3.19 (dq, *J* = 8.8 Hz, 2.8 Hz, 1H), 2.40 (dq, *J* = 2.6 Hz, 9.3 Hz, 1H), 2.29–2.19 (m, 2H), 2.15 (s, 3H), 2.0 (tdd, *J* = 3.1 Hz, 5.4 Hz, 12.9 Hz, 1H), 1.73–1.67 (m, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 176 MHz) δ: 148.7 (C), 147.4 (C), 137.6 (C), 137.1 (C), 135.5 (C), 135.1 (CH), 130.5 (CH), 130.1(CH), 127.5 (CH), 127.5 (CH), 126.8 (CH), 125.9 (CH), 125.5 (CH), 120.6 (CH), 111.7 (CH), 111.0 (CH), 56.0 (CH<sub>3</sub>), 55.9 (CH<sub>3</sub>), 48.2 (CH), 46.0 (CH), 28.2 (CH<sub>2</sub>), 24.7 (CH<sub>2</sub>), 19.8 (CH<sub>3</sub>).

(+)**11.** Colourless oil;  $[\alpha]^{25}_{D}$  +266 (*c* = 1, CH<sub>2</sub>Cl<sub>2</sub>). **HRMS** (EI, C<sub>23</sub>H<sub>26</sub>O<sub>2</sub>, M<sup>+</sup>): calcd.: 334.1933, found: 334.1930. **FTIR** (cast film): 3018, 2931, 2835, 1515, 1261, 1030 cm<sup>-1</sup>.

(-)11. Colourless oil;  $[\alpha]^{25}_{D}$  -201 (*c* = 1, CH<sub>2</sub>Cl<sub>2</sub>). **HRMS** (EI, C<sub>23</sub>H<sub>26</sub>O<sub>2</sub>, M<sup>+</sup>): 334.1933, found: 334.1928. **FTIR** (cast film): 3018, 2931, 2835, 1515, 1261, 1030 cm<sup>-1</sup>.

(±) 3(S/R)-(3,4-dimethoxyphenyl)-4(R/S)-[(Z)-2-methylstyryl]cyclohex-1-ene (16): <sup>1</sup>H NMR (CDCl<sub>3</sub>,

700MHz) δ: 7.07 (t, *J* = 7.4 Hz, 1H), 7.04 (d, *J* = 7.3, 1H) 7.0 (t, *J* = 7.4 Hz, 1H), 6.71 (d, *J* = 8.0 Hz, 1H), 6.58 (dt, *J* = 1.7 Hz, 8.4 Hz, 2H), 6.38 (d, *J* = 2.0 Hz, 1H), 6.27 (d, *J* = 11.3 Hz, 1H), 5.78 (dq, *J* = 9.8 Hz, 3.2 Hz, 1H), 5.60–5.57 (m, 2H), 3.85 (s, 3H), 3.64 (s, 3H), 3.10 (dq, *J* = 9.0 Hz, 2.8 Hz, 1H), 2.58 (dq, *J* = 2.8 Hz, 10.3 Hz, 1H), 2.16–2.13 (m, 2H), 1.87 (s, 3H), 1.81–1.77 (m, 1H), 1.66–1.60 (m, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 176 MHz) δ: 148.8 (C), 147.4 (C), 137.6 (C), 137.0 (C), 136.3 (CH<sub>2</sub>), 130.6 (CH<sub>2</sub>), 129.3 (CH), 128.8 (CH<sub>2</sub>), 128.4 (CH), 127.1 (CH), 126.6 (CH), 125.0 (CH), 120.5 (CH<sub>2</sub>), 110.9 (CH), 110.8 (CH), 56.0 (CH<sub>3</sub>), 55.7 (CH<sub>3</sub>), 48.2 (CH), 40.7 (CH), 28.7 (CH<sub>2</sub>), 24.4 (CH<sub>2</sub>), 19.5 (CH<sub>3</sub>).

(+) **16.** White solid;  $[\alpha]^{25}_{D}$  +64 (c = 1.00, CH<sub>2</sub>Cl<sub>2</sub>). **HRMS** (EI, C<sub>23</sub>H<sub>26</sub>O<sub>2</sub>, M<sup>+</sup>): calcd.: 334.1933, found: 334.1934. **FTIR** (cast film): 3018, 2924, 2835, 1516, 1261, 1031 cm<sup>-1</sup>.

(-)16. White solid;  $[\alpha]^{25}_{D}$  -43 (c = 1.00, CH<sub>2</sub>Cl<sub>2</sub>). **HRMS** (EI, C<sub>23</sub>H<sub>26</sub>O<sub>2</sub>, M<sup>+</sup>): calcd.: 334.1933, found: 334.1928. **FTIR** (cast film): 3018, 2928, 2834, 1516, 1261, 1031 cm<sup>-1</sup>.

|         | silica column   | product   | separation method     | HPLC      | isol    |          |                      |      |
|---------|-----------------|-----------|-----------------------|-----------|---------|----------|----------------------|------|
| product | conditions      | (% yield) |                       | injection |         | amount   | R <sub>t</sub> (min) | æ    |
|         |                 |           |                       |           | (+) 12E | 18 mg    | 13.1                 | >99% |
| 12E     | 20% EtOAc/hex   | 71 mg     | i-amylose-3 column.   | 70 m a    | (-) 12E | 18 mg    | 17.0                 | 99%  |
| 12Z     | $R_{\rm f}=0.3$ | (29%)     | 97% hex/EtOH (30 min) | 70 mg     | (+) 12Z | not      | 11.4                 | -    |
|         |                 |           |                       |           | (-) 12Z | isolated | 14.8                 | -    |

(±) 3(*S*/*R*)-(3,4-dimethoxyphenyl)-4(*R*/*S*)-[(*E*)-2-bromostyryl]cyclohex-1-ene (12):

<sup>1</sup>**H NMR** (CDCl<sub>3</sub>, 700MHz)  $\delta$ : 7.48 (dd, *J* = 7.9 Hz, 1.2 Hz, 1H), 7.40 (dd, *J* = 7.8Hz, 1.5 Hz, 1H), 7.20 (dt, *J* = 0.8 Hz, 7.5 Hz, 1H), 7.03 (dt, *J* = 1.5 Hz, 7.7 Hz, 1H), 6.80 (d, *J* = 8.2 Hz, 1H), 6.74 (dd, *J* = 8.1 Hz, 2.0 Hz, 1H), 6.72 (d, *J* = 2.1 Hz, 1H), 6.53 (d, *J* = 15.8 Hz, 1H), 6.10 (dd, *J* = 7.6 Hz, 15.9 Hz, 1H), 5.9 (tdd, *J* = 2.5 Hz, 4.6 Hz, 10.0 Hz, 1H), 5.68 (dq, *J* = 10.0 Hz, 2.2 Hz, 1H), 3.85 (s, 3H), 3.85 (s, 3H),

3.22 (dq, *J* = 11.1 Hz, 2.8 Hz, 1H), 2.46 (dq, *J* = 2.1 Hz, 9.0 Hz, 1H), 2.29–2.19 (m, 2H), 1.97 (tdd, *J* = 3.1 Hz, 5.1 Hz, 12.9 Hz, 1H), 1.74–1.68 (m, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 176 MHz) δ: 148.8 (C), 147.5(C), 137.7 (C), 137.4 (C), 137.2 (CH), 132.8 (CH), 130.4 (CH), 128.3 (CH), 128.2 (CH), 127.5 (CH), 127.3 (CH), 126.9 (CH), 123.3 (C), 120.5 (CH), 111.6 (CH), 111.1 (CH), 55.9 (CH<sub>3</sub>), 55.9 (CH<sub>3</sub>), 48.0 (CH), 45.3 (CH), 27.7 (CH<sub>2</sub>), 24.6 (CH<sub>2</sub>).

(+)**12E:** Colourless oil;  $[\alpha]^{25}_{D}$  +214 (*c* = 1.00, CH<sub>2</sub>Cl<sub>2</sub>). **HRMS** (EI, C<sub>22</sub>H<sub>23</sub>BrO<sub>2</sub>, M<sup>+</sup>): calcd.: 400.0861, found: 400.0861. **FTIR** (cast film): 3018, 2930, 2834, 1515, 1465, 1261, 1139, 1029 cm<sup>-1</sup>.

(-)12E: Colourless oil;  $[\alpha]^{25}_{D}$  –230 (c = 0.99, CH<sub>2</sub>Cl<sub>2</sub>). **HRMS** (EI, C<sub>22</sub>H<sub>23</sub>BrO<sub>2</sub>, M<sup>+</sup>): calcd.: 400.0861, found: 400.0871. **FTIR** (cast film): 3018, 2930, 2834, 1515, 1465, 1261, 1139, 1029 cm<sup>-1</sup>.

(±) 3(S/R)-(3,4-dimethoxyphenyl)-4(R/S)-[(Z)-3,4-dimethoxystyryl]cyclohex-1-ene (13):

| nuaduat | silica column                   | product         | concretion method  | HPLC      |                 |                   | isolated components   |                   |                       |     |  |
|---------|---------------------------------|-----------------|--|-----------|-----------------|-------------------|-----------------------|-------------------|-----------------------|-----|--|
| product | conditions                      | (% yield)       | separation metrou  | injection |                 | mass <sub>a</sub> | R <sub>ta</sub> (min) | mass <sub>b</sub> | R <sub>tb</sub> (min) | ee  |  |
|         |                                 |                 | sequential runs:   |           | (+) <b>t-BG</b> | 144 mg            | 12.0                  | 67 mg             | 11.9                  | 99% |  |
| t-BG    | 20% EtOAc/hex $R_{\rm f} = 0.3$ | 527 mg<br>(77%) | a. AD-H column. 18%<br><sup>i</sup> PrOH/CO <sub>2</sub><br>b. C8 column. 50→100%<br>ACN/H <sub>2</sub> O (30 min) | 479 mg    | (-) <b>t-BG</b> | 146 mg            | 15.2                  | 50 mg             | 11.9                  | 93% |  |
| 13      |                                 |                 |  |           | (+) 13Z         | 44 mg             | 9.4                   | 12 mg             | 10.1                  | 96% |  |
|         |                                 |                 |  |           | (-) 13Z         | 50 mg             | 10.8                  | 18 mg             | 10.1                  | 95% |  |

\*HPLC Method B used to remove minor impurities

<sup>1</sup>**H NMR** (CDCl<sub>3</sub>, 700MHz) δ: 6.72 (d, *J* = 8.2 Hz, 1H), 6.70 (d, *J* = 8.1 Hz, 1H), 6.65 (dd, *J* = 2.1 Hz, 8.2 Hz, 1H), 6.56 (d, *J* = 2.1 Hz, 1H), 6.43–6.41 (m, 2H), 6.27 (d, *J* = 11.5 Hz, 1H), 5.84 (tdd, *J* = 2.4 Hz, 4.2 Hz, 10.1 Hz, 1H), 5.65 (dq, *J* = 2.2 Hz, 9.8 Hz, 1H), 5.51 (dd, *J* = 10.4 Hz, 11.5 Hz), 3.84 (s, 3H), 3.83 (s, 3H), 3.76 (s, 3H), 3.73 (s, 3H), 3.15 (dq, *J* = 8.8 Hz, 2.8 Hz, 1H), 2.84 (dq, *J* = 2.5 Hz, 10.1 Hz, 1H), 2.19–2.15 (m, 2H), 1.83 (tdd, *J* = 3.1 Hz, 5.0 Hz, 12.8 Hz, 1H), 1.67–1.61 (m, 1H). <sup>13</sup>**C NMR** (CDCl<sub>3</sub>, 176 MHz) δ: 148.7, 148.4, 147.6, 147.4, 137.4, 135.9, 130.7, 130.5, 128.5, 127.3, 120.8, 120.3, 111.8, 111.3, 110.8, 110.8, 55.9, 55.8, 55.7, 48.1, 40.7, 28.6, 24.5. Characterization data is consistent with literature.<sup>7</sup>

(+) **t- BG:** Colourless oil:  $[\alpha]^{25}_{D}$  +325 (c = 1.00, CH<sub>2</sub>Cl<sub>2</sub>). (-) **t-BG:** Colourless oil:  $[\alpha]^{25}_{D}$  -275 (c = 1.00, CH<sub>2</sub>Cl<sub>2</sub>). (+)**13:** Colourless oil:  $[\alpha]^{25}_{D}$  +6.4(c = 1.00, CH<sub>2</sub>Cl<sub>2</sub>). (-)**13:** Colourless oil:  $[\alpha]^{25}_{D}$  -3.3 (c = 1.90, CH<sub>2</sub>Cl<sub>2</sub>).

| n vo d v ot | silica column | product   | concretion mathed     | HPLC      | isol    | ated compo | nents                |
|-------------|---------------|-----------|-----------------------|-----------|---------|------------|----------------------|
| product     | conditions    | (% yield) | separation method     | injection |         | amount     | R <sub>t</sub> (min) |
| 17E         | 15% EtOAc/hex | 66 mg     | i-amylose-3 column.   | 50 mg     | (±) 17E | 22 mg      | 7.8                  |
| 17Z         | $R_{f} = 0.2$ | (52%)     | 97% hex/EtOH (20 min) | 50 mg     | (±) 17Z | not is     | olated               |

(±) 3(S/R)-(3-methoxyphenyl)-4(R/S)-[(E)-3,4-dimethoxystyryl]cyclohex-1-ene (17):

**17E:** White oil. <sup>1</sup>**H NMR** (CDCl<sub>3</sub>, 700MHz)  $\delta$ : 7.19 (t, J = 7.8 Hz, 1H), 6.82–6.73 (m, 6H), 6.13 (d, J = 15.9 Hz, 1H), 6.03 (dd, J = 7.6 Hz, 16.0 Hz 1H), 5.90 (tdd, J = 2.4 Hz, 4.0 Hz, 10.0 Hz, 1H), 5.68 (dq, J = 10.0 Hz, 2.1 Hz, 1H), 3.88 (s, 3H), 3.86 (s, 3H), 3.77 (s, 3H), 3.23 (dq, J = 9.4 Hz, 2.7 Hz, 1H), 2.41 (dq, J = 2.6 Hz, 9.3 Hz, 1H), 2.26–2.18 (m, 2H), 1.92 (dq, J = 12.5 Hz, 4.2 Hz, 1H), 1.70–1.64 (m, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 176 MHz)  $\delta$ : 159.5 (C), 149.0 (C), 148.3 (C), 146.7 (C), 132.2 (CH), 131.1 (C), 130.0 (CH), 129.0 (CH), 128.9 (CH), 127.6 (CH), 121.1 (CH), 118.9 (CH), 114.3 (CH), 111.5 (CH), 111.2 (CH), 108.8 (CH), 56.0 (CH<sub>3</sub>), 55.8 (CH<sub>3</sub>), 55.2 (CH<sub>3</sub>), 48.5 (CH), 45.1 (CH), 27.8 (CH<sub>2</sub>), 24.5 (CH<sub>2</sub>). **HRMS** (EI, C<sub>23</sub>H<sub>26</sub>O<sub>3</sub>, M<sup>+</sup>): calcd.: 350.1882, found: 350.1874. **FTIR** (cast film): 3019, 2931, 2835, 1601, 1515, 1465, 1263, 1157, 1028 cm<sup>-1</sup>.

(±) (3(S/R)-(4-methoxyphenyl)-4(R/S)-[(E)-3,4-dimethoxystyryl]cyclohex-1-ene (18):

| nroduct | silica column | product   | sonaration method     | HPLC      | isol    | ated compo | onents               |
|---------|---------------|-----------|-----------------------|-----------|---------|------------|----------------------|
| product | conditions    | (% yield) | separation method     | injection |         | amount     | R <sub>t</sub> (min) |
| 18E     | 20% EtOAc/hex | 206 mg    | i-amylose-3 column.   | 100 m a   | (±) 18E | 22 mg      | 9.2                  |
| 18Z     | $R_{f} = 0.2$ | (85%)     | 97% hex/EtOH (10 min) | 100 mg    | (±) 18Z | not is     | olated               |

<sup>1</sup>**H NMR** (CDCl<sub>3</sub>, 500MHz) δ: 7.12–7.09 (m, 2H), 6.83–6.76 (m, 5H), 6.11 (d, J = 16.0 Hz, 1H), 6.02 (dd, J = 7.4 Hz, 16.0 Hz, 1H), 5.89 (dq, J = 10.0, 3.3 Hz, 1H), 5.66 (dq, J = 10 Hz, 2.2 Hz, 1H), 3.88 (s, 3H), 3.86 (s, 3H), 3.78 (s, 3H), 3.20 (dq, J = 11.0 Hz, 2.8 Hz, 1H), 2.36 (dq, J = 2.9 Hz, 9.8 Hz, 1H), 2.24–2.19 (m, 2H), 1.91 (dq, J = 12.5 Hz, 4.2 Hz, 1H), 1.70–1.63 (m, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 126 MHz) δ: 158.0 (C), 149.0 (C), 148.3 (C), 137.1 (C), 132.3 (C), 131.1 (CH), 130.5 (CH), 129.4 (2 CH), 128.8 (CH), 127.4 (CH), 118.8 (CH), 113.6 (2 CH), 111.2 (CH), 108.8 (CH), 56.0 (CH<sub>3</sub>), 55.9 (CH<sub>3</sub>), 55.263 (CH<sub>3</sub>), 47.6 (CH), 45.5 (CH), 27.9 (CH<sub>2</sub>), 24.6 (CH<sub>2</sub>). **HRMS** (EI, C<sub>23</sub>H<sub>26</sub>O<sub>3</sub>, M<sup>+</sup>): calcd.: 350.1882, found: 350.1878. **FTIR** (cast film): 3018, 2931, 2835, 1608, 1513, 1262, 1139, 1029 cm<sup>-1</sup>.

(±) 3(S/R)-(3-methoxy-4-hydroxyphenyl)-4(R/S)-[(E)-3,4-dimethoxystyryl]cyclohex-1-ene (19):



| product | silica column<br>conditions        | product<br>mass<br>(% vield) | separation method             | HPLC<br>injection | isol    | ated compo | <b>nents</b><br>R <sub>t</sub> (min) |
|---------|------------------------------------|------------------------------|-------------------------------|-------------------|---------|------------|--------------------------------------|
| 19E     | $10 \rightarrow 25\%$<br>EtOAc/bex | 40 mg                        | C8 column. 50→100%            | 10 m a            | (±) 19E | 8 mg       | 18.0                                 |
| 19Z     | $R_{\rm f} = 0.2$                  | (32%)                        | ACN/H <sub>2</sub> O (30 min) | 40 mg             | (±) 19Z | not is     | olated                               |

<sup>1</sup>**H NMR** (CDCl<sub>3</sub>, 500MHz) δ: 6.83–6.76 (m, 4H), 6.70–6.67 (m, 2H), 6.10 (d, *J* = 16.0 Hz, 1H), 6.02 (dd, *J* = 16.0 Hz, 7.5 Hz, 1H), 5.91–5.87 (m, 1H), 5.67 (dq, *J* = 10.5 Hz, 2.5 Hz, 1H), 5.45 (s, 1H), 3.87 (s, 3H), 3.86 (s, 3H), 3.82 (s, 3H), 3.17–3.15 (m, 1H), 2.35–2.33 (m, 1H), 2.22–2.20 (m, 2H), 1.93–1.90 (m, 1H), 1.69–1.64 (m, 1H). Characterization data are consistent with literature.<sup>7</sup>

\*Synthesized via 5d without racemization to 6d

## Synthesis of 24 and 25:

Pd/C (5 mg) was added to a flame dried flask under N<sub>2</sub> followed by (±) *t*-BG or (±)*c*-BG (25.0 mg, 0.06 mmol) in ethyl acetate. After a quick exposure to vacuum, then N<sub>2</sub>, the flask was placed under reduced pressure. A hydrogen (H<sub>2</sub>) balloon was inserted, and the reaction was then stirred for 18 hours. The contents of the flask were filtered through celite and rinsed with CH<sub>2</sub>Cl<sub>2</sub>. The solvent was concentrated in vacuo, providing products **24** and **25** without the need for further purification.

(±) 4-((1*R*,2*S*)-2-(3,4-dimethoxyphenylethy)cyclohexyl)-1,2-dimethoxy benzene (24): White solid (99%). <sup>1</sup>H NMR (CDCl<sub>3</sub>,700 MHz)  $\delta$ : 6.75 (d, *J* = 7.7 Hz, 1H), 6.70 (d, *J* = 7.7 Hz, 1H), 6.62 (dd, *J* = 7.7 Hz, 1.4 Hz, 1H), 6.59 (d, *J* = 1.4 Hz, 1H), 6.51 (dd, *J* = 7.7 Hz, 1.4 Hz, 1H), 6.46 (d, *J* = 1.4 Hz, 1H), 3.84 (s, 3H), 3.82 (s, 3H), 3.81 (s, 3H), 3.77 (s, 3H), 2.56–2.52 (m, 1H), 2.32–2.27 (m, 1H), 2.17–2.14 (m, 1H), 2.06–2.02 (m, 1H), 1.82–.77 (m, 3H), 1.52–1.42 (m, 2H), 1.39–1.31 (m, 3H), 1.20–1.16 (m, 1H), 1.10, 1.04 (m, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>,175 MHz)  $\delta$ : 148.7, 148.6, 147.0, 146.9, 139.4, 135.4, 120.0, 119.5, 111.6, 111.0, 110.6, 55.9, 55.8, 55.7, 55.7, 50.4, 41.5, 36.3, 35.9, 32.2, 32.1, 26.9, 26.5. HRMS (EI, C<sub>24</sub>H<sub>32</sub>O<sub>4</sub>, M<sup>+</sup>): calcd: 385.2301, found: 385.2342.

(±) 4-((1S,2S)-2-(3,4-dimethoxyphenylethy)cyclohexyl)-1,2-dimethoxy benzene (25): White solid (95%). <sup>1</sup>H NMR (CDCl<sub>3</sub>,700 MHz)  $\delta$ : 6.77 (d, *J* = 8.4 Hz, 1H), 6.69 (d, *J* = 8.4 Hz, 1H), 6.67 (dd, *J* = 8.4, 1.4 Hz, 1H), 6.65 (d, *J* = 1.4 Hz, 1H), 6.49 (dd, *J* = 7.7, 1.4 Hz, 1H), 6.45 (d, *J* = 1.4 Hz, 1H), 3.85 (s, 3H), 3.82 (app s, 6H), 3.77 (s, 3H), 2.80-2.77 (m, 1H), 2.48-2.45 (m, 1H), 2.14-2.11 (m, 1H), 1.89-1.85 (m, 3H), 1.75-1.67 (m, 2H), 1.59-1.46 (m, 4H), 1.41-1.37 (m, 1H), 1.31-1.26 (m, 1H) ppm. <sup>13</sup>C-NMR (CDCl<sub>3</sub>,175 MHz)  $\delta$ : 148.6, 148.5, 146.9, 146.9, 138.5, 135.3, 120.0, 119.2, 111.6, 111.2, 111.0, 110.7, 55.9, 55.9, 55.8, 55.7, 45.9, 39.3, 33.6, 29.6, 27.3, 26.5, 25.7, 20.6HRMS (EI, C<sub>24</sub>H<sub>32</sub>O<sub>4</sub>, M<sup>+</sup>): calcd: 385.2301, found: 385.2342.

#### Synthesis of 26 and 27<sup>14</sup>



Rhodium acetate dimer (1 mg) and a solution of (±)*t*-BG (50 mg, 0.13 mmol) or (±)*c*-BG (24 mg, 0.06 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (0.50 mL) was added to a flame dried round bottom flask. The reaction solution was stirred while ethyl diazoacetate (33 wt% CH<sub>2</sub>Cl<sub>2</sub> solution, 16  $\mu$ L dissolve in 0.5 mL CH<sub>2</sub>Cl<sub>2</sub> for t-BG and 8  $\mu$ L dissolve in 0.5 mL CH<sub>2</sub>Cl<sub>2</sub> for c-BG) was added dropwise. The reaction was stirred at rt for 3 hours and then concentrated in vacuo. The residue was dissolved in acetonitrile and was purified by HPLC

| product | separation method                    | product mass<br>(% yield) | R <sub>t</sub> (min) |
|---------|--------------------------------------|---------------------------|----------------------|
| 26      | C8 column.<br>$50 \rightarrow 100\%$ | 9.4 mg (16%)              | 17.8                 |
| 27      | $ACN/H_2O$ (20 min)                  | 4.5 mg (15%)              | 9.9                  |

(±) **1-((1***R*,2*S*,3*S*,6*R*,7*S*)-3-(3,4-dimethoxyphenethyl)-2-(3,4-dimethoxyphenyl)bicyclo[4.1.0]heptan-7yl)-2-methoxyethanone (26): Yellow oil (16%). <sup>1</sup>H NMR (CDCl<sub>3</sub>,700 MHz)  $\delta$ : 6.80 (m, 2H), 6.73–6.72 (m, 2H), 6.70–6.69 (m, 2H), 5.92 (d, *J* = 16.1 Hz, 1H), 5.73 (dd, *J* = 16.1 Hz, 7.7 Hz, 1H), 4.10–4.05 (m, 2H), 3.83 (s, 6H), 3.83 (s, 3H), 3.82 (s, 3H), 2.55 (dd, *J* = 10.5 Hz, 0.7 Hz, 1H), 2.16–2.14 (m, 1H), 2.05–1.98 (m, 2H), 1.86–1.84 (m, 1H), 1.75–1.69 (m, 2H), 1.59 (app t, *J* = 4.2 Hz, 1H), 1.23 (t, *J* = 7 Hz, 3H),1.16 (dd, *J* = 12.6 Hz, 4.2 Hz, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>,175 MHz)  $\delta$ : 174.1, 148.9, 148.7, 148.3, 147.3, 139.0, 131.8, 130.8, 129.0, 120.2, 118.7, 111.4, 111.1, 111.0, 108.7, 60.4, 55.9, 55.9, 55.8, 55.7, 28.2, 25.7, 25.4, 23.3, 22.5, 14.3. HRMS (EI, C<sub>28</sub>H<sub>35</sub>O<sub>6</sub>, [M+H]<sup>+</sup>): calcd: 467.2355, found: 467.2439. (±) 1-((1*R*,2*R*,3*S*,6*R*,7*S*)-3-(3,4-dimethoxyphenethyl)-2-(3,4-dimethoxyphenyl)bicyclo[4.1.0]heptan-7-yl)-2-methoxyethanone (27): Yellow oil (15%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 700 MHz)  $\delta$ : 6.88 (dd, *J* = 7.7 Hz, 2.1 Hz, 1H), 6.81 (d, *J* = 7.7 Hz, 1H), 6.76 (d, *J* = 2.1 Hz, 2H), 6.74 (dd, *J* = 7.7 Hz, 2.1 Hz, 2H), 6.17 (d, *J* = 16.1 Hz, 1H), 5.60 (dd, *J* = 16.1 Hz, 9.1 Hz, 1H), 4.12 (q, *J* = 7 Hz, 2H), 3.86 (s, 3H), 3.85 (s, 3H), 3.83 (s, 3H), 3.74 (s, 3H), 3.23 (app. d, *J* = 4.9 Hz, 1H), 2.29–2.23 (m, 2H), 1.89 (appt, *J* = 4.2 Hz, 2H), 1.82–1.78 (m, 1H), 1.60 (t, *J* = 4.2 Hz, 1H), 1.52–1.48 (m, 1H), 1.27–1.21 (m, 4H). <sup>13</sup>C NMR (CDCl<sub>3</sub> ,175 MHz)  $\delta$ : 174.2, 148.9, 148.4, 148.1, 147.5, 134.9, 131.3, 130.7, 129.1, 121.3, 118.8, 113.3, 111.2, 110.5, 108.6, 60.4, 55.9, 55.8, 55.7, 43.7, 40.0, 28.3, 26.2, 23.1, 20.9, 20.8, 14.3. HRMS (EI, C<sub>28</sub>H<sub>36</sub>O<sub>6</sub>, [M+H]<sup>+</sup>): calcd: 467.2355, found: 467.2442.

#### **Optical Purity Data**

Enantiomeric excess (% ee) was determined by chiral HPLC analysis, with one of the following methods:

- (a) 5% IPA: Hexane. Daicel CHIRALPAK IG column.
- (b) 20% isopropanol/CO<sub>2</sub>, 100 bar. Daicel CHIRALPAK AD-H column.
- (c) 10% IPA: Hexane. Daicel CHIRALPAK IC column.

\* Absolute stereochemistry was assigned according to published data in ref. 7

#### 8. (±) 3(*S*/*R*)-(3,4-dimethoxyphenyl)-4(*R*/*S*)-[(*E*)-styryl]cyclohex-1-ene: (Method a)



Signal 1: DAD1 A, Sig=254,4 Ref=360,100

| Peak<br># | RetTime<br>[min] | Туре | Width<br>[min] | Area<br>[mAU*s] | Height<br>[mAU] | Area<br>% |
|-----------|------------------|------|----------------|-----------------|-----------------|-----------|
|           |                  |      |                |                 |                 |           |
| 1         | 3.275            | MM   | 0.1110         | 4269.88037      | 640.98907       | 48.6412   |
| 2         | 4.451            | MM   | 0.1608         | 4508.44580      | 467.26389       | 51.3588   |
|           |                  |      |                |                 |                 |           |
| Total     | s :              |      |                | 8778.32617      | 1108.25296      |           |







(-)8. 3(*R*)-(3,4-dimethoxyphenyl)-4(*S*)-[(*E*)-styryl]cyclohex-1-ene (> 99% ee): (Method a)

Signal 1: DAD1 A, Sig=254,4 Ref=360,100

| Peak<br># | RetTime<br>[min] | Туре | Width<br>[min] | Area<br>[mAU*s] | Height<br>[mAU] | Area<br>% | Description |
|-----------|------------------|------|----------------|-----------------|-----------------|-----------|-------------|
| 1         | 4.475            | MM   | 0.1612         | 2.05837e4       | 2128.18555      | 100.0000  | (–)8        |
| Total     | s :              |      |                | 2.05837e4       | 2128.18555      |           |             |

#### 9. 3(S/R)-(3,4-dimethoxyphenyl)-4(R/S)-[(E)-3-methoxystyryl]cyclohex-1-ene: (Method a)



Signal 1: DAD1 A, Sig=254,4 Ref=360,100

Totals :

| Peak | RetTime | Туре | Width  | Area      | Height     | Area    |
|------|---------|------|--------|-----------|------------|---------|
| #    | [min]   |      | [min]  | [mAU*s]   | [mAU]      | %       |
|      |         |      |        |           |            |         |
| 1    | 5.762   | MM   | 0.1832 | 572.23199 | 52.04971   | 1.4663  |
| 2    | 6.236   | MM   | 0.2170 | 1.91519e4 | 1471.11340 | 49.0750 |
| 3    | 8.519   | MF   | 0.3142 | 1.90123e4 | 1008.52759 | 48.7173 |
| 4    | 8.997   | FM   | 0.1510 | 289.30722 | 31.94090   | 0.7413  |
|      |         |      |        |           |            |         |

3.90258e4 2563.63160



## (+)9. 3(S)-(3,4-dimethoxyphenyl)-4(R)-[(E)-3-methoxystyryl]cyclohex-1-ene(>99% ee): (Method a)

Peak RetTime Type Width Height Area Area Description [min] [min] [mAU\*s] [mAU] % # \_ \_ \_ \_ \_ \_ \_ \_ ----|-----|----|-----|------| ----| 0.2057 1023.30310 Impurity 5.785 MM 82.91499 3.5128 1 2 6.250 MM 0.2190 2.81073e4 2139.51660 96.4872 (+)9 Totals : 2.91306e4 2222.43159

#### (-)9. 3(*R*)-(3,4-dimethoxyphenyl)-4(*S*)-[(*E*)-3-methoxystyryl]cyclohex-1-ene(>99% ee): (Method a)



Signal 1: DAD1 A, Sig=254,4 Ref=360,100

| Peak<br># | RetTime<br>[min] | Туре | Width<br>[min] | Area<br>[mAU*s] | Height<br>[mAU] | Area<br>% | Description |
|-----------|------------------|------|----------------|-----------------|-----------------|-----------|-------------|
|           |                  |      |                |                 |                 |           |             |
| 1         | 6.333            | MM   | 0.2538         | 37.55331        | 2.46581         | 0.1881    | (+)9        |
| 2         | 8.569            | MF   | 0.3149         | 1.95090e4       | 1032.60400      | 97.7390   | (–)9        |
| 3         | 9.001            | FM   | 0.1763         | 413.75418       | 39.11983        | 2.0729    | Impurity    |
|           |                  |      |                |                 |                 |           |             |

Totals : 1.99603e4 1074.18965



#### 14. 3(*S*/*R*)-(3,4-dimethoxyphenyl)-4(*R*/*S*)-[(*Z*)-3-methoxystyryl]cyclohex-1-ene: (Method a)

Signal 1: DAD1 A, Sig=254,4 Ref=360,100

| Peak<br># | RetTime<br>[min] | Туре | Width<br>[min] | Area<br>[mAU*s] | Height<br>[mAU] | Area<br>% |
|-----------|------------------|------|----------------|-----------------|-----------------|-----------|
|           |                  |      |                |                 |                 |           |
| 1         | 4.775            | MM   | 0.1600         | 3783.56592      | 394.04947       | 50.1046   |
| 2         | 6.001            | MM   | 0.2238         | 3767.76880      | 280.64569       | 49.8954   |
|           |                  |      |                |                 |                 |           |
| Total     | s :              |      |                | 7551.33472      | 674.69516       |           |

#### (+)14. 3(*S*)-(3,4-dimethoxyphenyl)-4(*R*)-[(*Z*)-3-methoxystyryl]cyclohex-1-ene (>99% ee): (Method a)



Signal 1: DAD1 A, Sig=254,4 Ref=360,100

| Peak<br># | RetTime<br>[min] | Туре | Width<br>[min] | Area<br>[mAU*s] | Height<br>[mAU] | Area<br>% | Description |
|-----------|------------------|------|----------------|-----------------|-----------------|-----------|-------------|
|           |                  |      |                |                 |                 |           |             |
| 1         | 4.167            | MM   | 0.1578         | 67.01202        | 7.07963         | 1.5252    | Impurity    |
| 2         | 4.509            | MF   | 0.1259         | 40.99306        | 5.42767         | 0.9330    | Impurity    |
| 3         | 4.760            | FM   | 0.1605         | 4285.70508      | 444.97592       | 97.5418   | (+)14       |
|           |                  |      |                |                 |                 |           |             |
| Total     | s :              |      |                | 4393.71016      | 457.48322       |           |             |





Signal 1: DAD1 A, Sig=254,4 Ref=360,100

| Peak<br># | RetTime<br>[min] | Туре   | Width<br>[min] | Area<br>[mAU*s] | Height<br>[mAU] | Area<br>% | Description |
|-----------|------------------|--------|----------------|-----------------|-----------------|-----------|-------------|
| <br>1     | 6.000            | <br>MM | 0.2197         | <br>4306.78857  | 326.78674       | 100.0000  | ()14        |
| Total     | s :              |        |                | 4306.78857      | 326.78674       |           |             |





Signal 1: DAD1 A, Sig=254,4 Ref=360,100

| Peak | RetTime | Туре | Width  | Area      | Height     | Area    |
|------|---------|------|--------|-----------|------------|---------|
| #    | [min]   |      | [min]  | [mAU*s]   | [mAU]      | %       |
|      |         |      |        |           |            |         |
| 1    | 6.822   | MM   | 0.2920 | 318.83115 | 18.19932   | 0.7639  |
| 2    | 7.481   | MM   | 0.2679 | 2.08579e4 | 1297.71582 | 49.9733 |
| 3    | 9.423   | MM   | 0.3424 | 440.60825 | 21.44956   | 1.0557  |
| 4    | 10.730  | MM   | 0.4021 | 2.01207e4 | 833.89203  | 48.2072 |
|      |         |      |        |           |            |         |

Totals : 4.17381e4 2171.25673



(+)10. 3(*S*)-(3,4-dimethoxyphenyl)-4(*R*)-[(*E*)-4-methoxystyryl]cyclohex-1-ene (>99% ee): (Method a)

Signal 1: DAD1 A, Sig=254,4 Ref=360,100

| Peak<br>#  | RetTime<br>[min] | Туре     | Width<br>[min]   | Area<br>[mAU*s]        | Height<br>[mAU]        | Area<br>%         | Description       |
|------------|------------------|----------|------------------|------------------------|------------------------|-------------------|-------------------|
| <br>1<br>2 | 6.818<br>7.470   | MM<br>MM | 0.2138<br>0.2671 | 148.12431<br>2.22274e4 | 11.54741<br>1386.85339 | 0.6620<br>99.3380 | Impurity<br>(+)10 |
| Total      | s :              |          |                  | 2.23755e4              | 1398.40080             |                   |                   |

(-)10. 3(*R*)-(3,4-dimethoxyphenyl)-4(*S*)-[(*E*)-4-methoxystyryl]cyclohex-1-ene (99% ee): (Method a)



Signal 1: DAD1 A, Sig=254,4 Ref=360,100

| Peak<br># | RetTime<br>[min] | Туре | Width<br>[min] | Area<br>[mAU*s] | Height<br>[mAU] | Area<br>% | Description |
|-----------|------------------|------|----------------|-----------------|-----------------|-----------|-------------|
|           |                  |      |                |                 |                 |           |             |
| 1         | 6.733            | MM   | 0.2292         | 20.99214        | 1.10117         | 0.1393    | Impurity    |
| 2         | 7.431            | MM   | 0.3088         | 73.65749        | 3.97611         | 0.4887    | (+)10       |
| 3         | 9.296            | MM   | 0.3646         | 362.90045       | 16.59074        | 2.4080    | Impurity    |
| 4         | 10.607           | MM   | 0.4010         | 1.46134e4       | 607.34192       | 96.9640   | (-)10       |
|           |                  |      |                |                 |                 |           |             |

Totals: 1.50709e4 629.00994



15. 3(*S*/*R*)-(3,4-dimethoxyphenyl)-4(*R*/*S*)-[(*Z*)-4-methoxystyryl]cyclohex-1-ene: (Method a)

(+) 15. 3(S)-(3,4-dimethoxyphenyl)-4(R)-[(Z)-4-methoxystyryl]cyclohex-1-ene (98% ee): (Method a)



Signal 1: DAD1 A, Sig=254,4 Ref=360,100

| Peak<br># | RetTime<br>[min] | Туре         | Width<br>[min] | Area<br>[mAU*s] | Height<br>[mAU] | Area<br>% | Description    |
|-----------|------------------|--------------|----------------|-----------------|-----------------|-----------|----------------|
| 1 2       | 5.992<br>7.532   | <br>MM<br>MM | 0.2014         | 4040.65259      | 334.44958       | 99.1590   | (-)15<br>(+)15 |
| 2         | 7.002            |              | 0.2000         | 04.20020        | 2.20000         | 0.0410    | (+)15          |

3.32363e4 2413.15369

Totals :

4074.92084 336.68266







Totals :

8778.69983 548.70400





Signal 1: DAD1 A, Sig=254,4 Ref=360,100

Peak RetTime Type Width Height Area Area [mAU\*s] # [min] [min] [mAU] % ----|-----|-----|------|------|------| ----| 1 3.710 MM 0.1154 1.29200e4 1865.38831 49.7547 2 5.226 MM 0.1773 1.30474e4 1226.50244 50.2453

Totals : 2.59673e4 3091.89075



(+) 11. 3(S)-(3,4-dimethoxyphenyl)-4(R)-[(E)-2-methylstyryl]cyclohex-1-ene (98%ee): (Method a)

(-) 11. 3(*R*)-(3,4-dimethoxyphenyl)-4(*S*)-[(*E*)-2-methylstyryl]cyclohex-1-ene (99%ee): (Method a)



Signal 1: DAD1 A, Sig=254,4 Ref=360,100

| Peak<br># | RetTime<br>[min] | Туре | Width<br>[min] | Area<br>[mAU*s] | Height<br>[mAU] | Area<br>% | Description |
|-----------|------------------|------|----------------|-----------------|-----------------|-----------|-------------|
|           |                  |      |                |                 |                 |           |             |
| 1         | 3.696            | MM   | 0.1361         | 120.48663       | 14.74946        | 0.3724    | (+)11       |
| 2         | 5.165            | MM   | 0.1827         | 3.22329e4       | 2940.39087      | 99.6276   | (-)11       |
|           |                  |      |                |                 |                 |           |             |

Totals: 3.23534e4 2955.14033



## 16. 3(*S*/*R*)-(3,4-dimethoxyphenyl)-4(*R*/*S*)-[(*Z*)-2-methylstyryl]cyclohex-1-ene: (Method a)

Signal 1: DAD1 A, Sig=254,4 Ref=360,100

| Peak<br># | RetTime<br>[min] | Туре | Width<br>[min] | Area<br>[mAU*s] | Height<br>[mAU] | Area<br>% |
|-----------|------------------|------|----------------|-----------------|-----------------|-----------|
|           |                  |      |                |                 |                 |           |
| 1         | 2.676            | MM   | 0.0916         | 747.41486       | 135.98724       | 52.8446   |
| 2         | 2.849            | MM   | 0.0947         | 134.14784       | 23.60262        | 9.4847    |
| 3         | 3.375            | MM   | 0.1194         | 532.80042       | 74.35267        | 37.6707   |
| Total     | s :              |      |                | 1414.36311      | 233.94253       |           |





Signal 1: DAD1 A, Sig=254,4 Ref=360,100

| Peak I | RetTime<br>[min] | Туре | Width<br>[min] | Area<br>[mAU*s] | Height<br>[mAU] | Area<br>% | Description |
|--------|------------------|------|----------------|-----------------|-----------------|-----------|-------------|
| -      |                  |      |                |                 |                 |           |             |
| 1      | 2.677            | MM   | 0.0911         | 2077.39697      | 380.17612       | 91.4516   | (+)16       |
| 2      | 2.849            | MM   | 0.0947         | 187.19553       | 32.93308        | 8.2408    | impurity    |
| 3      | 3.371            | MM   | 0.1600         | 6.98739         | 7.27885e-1      | 0.3076    | (-)16       |
|        |                  |      |                |                 |                 |           | · /         |
| Totals | s :              |      |                | 2271.57989      | 413.83708       |           |             |



(-)16. 3(*R*)-(3,4-dimethoxyphenyl)-4(*S*)-[(*Z*)-2-methylstyryl]cyclohex-1-ene (99% ee): (Method a)

Signal 1: DAD1 A, Sig=254,4 Ref=360,100

| Peak F<br># | RetTime<br>[min] | Туре | Width<br>[min] | Area<br>[mAU*s] | Height<br>[mAU] | Area<br>% | Description |
|-------------|------------------|------|----------------|-----------------|-----------------|-----------|-------------|
| -           |                  |      |                |                 |                 |           |             |
| 1           | 2.665            | MM   | 0.1076         | 11.27477        | 1.74601         | 0.4541    | (+)16       |
| 2           | 2.855            | MM   | 0.1014         | 343.70029       | 56.51110        | 13.8428   | impurity    |
| 3           | 3.378            | MM   | 0.1196         | 2127.91309      | 296.63055       | 85.7031   | (           |
| Totals      | s :              |      |                | 2482.88815      | 354.88767       |           |             |

12. 3(S/R)-(3,4-dimethoxyphenyl)-4(R/S)-[(E)-2-bromostyryl]cyclohex-1-ene: (Method a)



Signal 1: DAD1 A, Sig=254,4 Ref=360,100

| Peak       | RetTime        | Туре     | Width            | Area                   | Height                   | Area               |
|------------|----------------|----------|------------------|------------------------|--------------------------|--------------------|
| #          | [min]          |          | [min]            | [mAU*s]                | [mAU]                    | %                  |
| <br>1<br>2 | 4.529<br>6.721 | MM<br>MM | 0.1522<br>0.2411 | 1.63185e4<br>1.72312e4 | 1787.35388<br>1191.35974 | 48.6397<br>51.3603 |

Totals : 3.35496e4 2978.71362



(+)12. 3(S)-(3,4-dimethoxyphenyl)-4(R)-[(E)-2-bromostyryl]cyclohex-1-ene (>99% ee): (Method a)

(-)12. 3(*R*)-(3,4-dimethoxyphenyl)-4(*S*)-[(*E*)-2-bromostyryl]cyclohex-1-ene (99% ee): (Method a)



Signal 1: DAD1 A, Sig=254,4 Ref=360,100

| Peak<br># | RetTime<br>[min] | Туре | Width<br>[min] | Area<br>[mAU*s] | Height<br>[mAU] | Area<br>% | Description |
|-----------|------------------|------|----------------|-----------------|-----------------|-----------|-------------|
|           |                  |      |                |                 |                 |           |             |
| 1         | 4.537            | MM   | 0.1676         | 65.53897        | 6.51827         | 0.4414    | (+)12       |
| 2         | 6.734            | MM   | 0.2394         | 1.47828e4       | 1029.02100      | 99.5586   | (-)12       |
|           |                  |      |                |                 |                 |           |             |
| Total     | s :              |      |                | 1.48483e4       | 1035.53927      |           |             |

13. 3(*S*/*R*)-(3,4-dimethoxyphenyl)-4(*R*/*S*)-[(*Z*)-3,4-dimethoxystyryl]cyclohex-1-ene: (Method b)



(+)13. 3(S)-(3,4-dimethoxyphenyl)-4(R)-[(Z)-3,4-dimethoxystyryl]cyclohex-1-ene: (Method b)



| Index            | Time (min) | Area (%) 220 nm |
|------------------|------------|-----------------|
| impurity         | 8.18       | 0.715           |
| (+)13            | 8.61       | 93.027          |
| (-)13            | 9.74       | 0.717           |
| (+) <i>t</i> -BG | 11.86      | 2.579           |
| (-) <i>t</i> -BG | 14.32      | 2.961           |
| Total            |            | 100.00          |

(-)13. 3(*R*)-(3,4-dimethoxyphenyl)-4(S)-[(*Z*)-3,4-dimethoxystyryl]cyclohex-1-ene: (Method b)



| Index    | Time (min) | Area (%) 220 nm |
|----------|------------|-----------------|
| (+)13    | 8.82       | 2.051           |
| (-)13    | 9.71       | 96.518          |
| impurity | 10.43      | 1.368           |
| Total    |            | 100.00          |

Since this analytical method led to different retention times for (+) 13 and (-) 13 as compared to the trace 13 (which is a mixture of (+) 13, (-) 13, (+) t-BG and (-) t-BG) another round of analytical validation was done to establish the enantiomeric purity (spectra shown below). Due to limited material remaining, a mixture containing 85:15 of the two enantiomers was prepared. These enantiomers were dissolved in DMSO which results in a solvent peak at ~1.6 min, this peak was ignored while integrating these spectra.



## 15:85 of (+) 13: (-) 13: (Method b)

|       | Index | Name    | Start | Time  | End   | RT Offset | Quantity | Height | Area     | Area    |
|-------|-------|---------|-------|-------|-------|-----------|----------|--------|----------|---------|
|       |       |         | [Min] | [Min] | [Min] | [Min]     | [% Area] | [µV]   | [µV.Min] | [%]     |
| (+)13 | 1     | UNKNOWN | 2.85  | 3.05  | 3.19  | 0.00      | 15.95    | 192.6  | 29.1     | 15.946  |
| (-)13 | 2     | UNKNOWN | 3.19  | 3.35  | 3.81  | 0.00      | 84.05    | 883.9  | 153.3    | 84.054  |
|       |       |         |       |       |       |           |          |        |          |         |
|       | Total |         |       |       |       |           | 100.00   | 1076.5 | 182.4    | 100.000 |

(+)13. 3(S)-(3,4-dimethoxyphenyl)-4(R)-[(Z)-3,4-dimethoxystyryl]cyclohex-1-ene (96% ee): (Method b-round 2)



|       | Index | Name    | Start | Time  | End   | RT Offset | Quantity | Height | Area     | Area    |
|-------|-------|---------|-------|-------|-------|-----------|----------|--------|----------|---------|
|       |       |         | [Min] | [Min] | [Min] | [Min]     | [% Area] | [µV]   | [µV.Min] | [%]     |
| (+)13 | 1     | UNKNOWN | 2.90  | 3.08  | 3.30  | 0.00      | 98.31    | 511.5  | 82.2     | 98.311  |
| (-)13 | 2     | UNKNOWN | 3.30  | 3.30  | 3.52  | 0.00      | 1.69     | 13.3   | 1.4      | 1.689   |
|       |       |         |       |       |       |           |          |        |          |         |
|       | Total |         |       |       |       |           | 100.00   | 524.8  | 83.6     | 100.000 |

(-)13. 3(R)-(3,4-dimethoxyphenyl)-4(S)-[(Z)-3,4-dimethoxystyryl]cyclohex-1-ene (95% ee) : (Method b-round 2)



|       | Index | Name    | Start | Time  | End   | RT Offset | Quantity | Height | Area     | Area    |
|-------|-------|---------|-------|-------|-------|-----------|----------|--------|----------|---------|
|       |       |         | [Min] | [Min] | [Min] | [Min]     | [% Area] | [µV]   | [µV.Min] | [%]     |
| (+)13 | 1     | UNKNOWN | 2.92  | 3.08  | 3.20  | 0.00      | 2.42     | 36.2   | 5.3      | 2.416   |
| (-)13 | 2     | UNKNOWN | 3.20  | 3.37  | 3.77  | 0.00      | 97.58    | 1182.0 | 213.9    | 97.584  |
|       |       |         |       |       |       |           |          |        |          |         |
|       | Total |         |       |       |       |           | 100.00   | 1218.2 | 219.2    | 100.000 |


*t*-BG-3(*S*/*R*)-(3,4-Dimethoxyphenyl)-4(*R*/*S*)-[(*E*)-3,4-dimethoxystyryl]cyclohex-1-ene: (Method c)

Signal 1: DAD1 A, Sig=254,4 Ref=360,100

| Peak<br>#  | RetTime<br>[min] | Туре     | Width<br>[min]   | Area<br>[mAU*s]          | Height<br>[mAU]      | Area<br>%              |
|------------|------------------|----------|------------------|--------------------------|----------------------|------------------------|
| <br>1<br>2 | 34.363<br>41.874 | MM<br>MM | 1.4701<br>1.7187 | 7143.75244<br>6600.07324 | 80.99113<br>64.00153 | <br>51.9779<br>48.0221 |
| Tota       | ls:              |          |                  | 1.37438e4                | 144.99266            |                        |

#### (+)*t*-BG-3(*S*)-(3,4-Dimethoxyphenyl)-4(*R*)-[(*E*)-3,4-dimethoxystyryl]cyclohex-1-ene (99% ee): (Method c)



Signal 1: DAD1 A, Sig=254,4 Ref=360,100



(-) t-BG- 3(R)-(3,4-Dimethoxyphenyl)-4(S)-[(E)-3,4-dimethoxystyryl]cyclohex-1-ene (93% ee): (Method c)



Signal 1: DAD1 A, Sig=254,4 Ref=360,100

| Peak<br># | RetTime<br>[min] | Туре     | Width<br>[min]   | Area<br>[mAU*s]        | Height<br>[mAU]      | Area<br>%         | Description                          |
|-----------|------------------|----------|------------------|------------------------|----------------------|-------------------|--------------------------------------|
| 1<br>2    | 34.867<br>41.644 | MM<br>MM | 1.3973<br>1.7276 | 406.12741<br>1.08815e4 | 4.84431<br>104.97392 | 3.5980<br>96.4020 | (+) <i>t</i> -BG<br>(-) <i>t</i> -BG |
| Tota      | ls:              |          |                  | 1.12876e4              | 109.81823            |                   |                                      |

S38

# PC-12 cell assays procedures

### Cell line maintenance

PC-12 cells (CRL-1721) were obtained from ATCC and maintained in Dulbecco's modified Eagle's medium (DMEM) (Gibco<sup>TM</sup> LS11965092) containing 5% horse serum (HS) (Gibco<sup>TM</sup> LS10438018), 5% fetal bovine serum (FBS) (Gibco<sup>TM</sup> LS26050070) and 100 U/mL penicillin with 100 µg/mL streptomycin (1% Pen-Strep) (Gibco<sup>TM</sup> LS15140148). Cells were cultured for a month to reach passage 4 and then used for neuritogenesis assays. Living cells were counted using trypan blue exclusion staining.

# Coating with collagen IV

The assay to determine neuritogenesis was carried out in 96 well plates (Ibidi USA  $\mu$ -Plate 96 Well, ibiTreat -#1.5 polymer coverslip, #89626). Each well was coated with 4-6  $\mu$ g/cm<sup>2</sup> of Collagen IV (Sigma-C5533 - Collagen from human placenta Bornstein and Traub Type IV) dissolved in Hanks' balanced salt solution (HBSS). After overnight incubation at 8°C, the plates were sterilized with 70% ethanol and then washed with HBSS (3 times) to remove any residual ethanol.

# Neuritogenesis assay<sup>15</sup>

Passage 4 PC-12 cells (at 70% confluency) were seeded in the collagen-IV coated wells at a density of 2  $\times 10^4$  cells/cm<sup>2</sup> and cultured in DMEM medium containing 5% HS, 5% FBS and 1% Pen-Strep for 24 hours, then the medium was changed to DMEM containing 2% HS, 1% FBS and a given treatment was added (see below). The cells were cultured for a further 48 hours and then visualized and/or stained for analysis.

*Treatments*: All the test compounds and commercial inhibitors were dissolved in DMSO and added as a solution. Compounds were tested at 30  $\mu$ M concentration, unless otherwise noted. The final concentration of DMSO does not exceed 0.6% in any test. NGF (10ng/mL) with 0.6% DMSO was used as the positive control and 0.6% DMSO as the negative control.

For testing the perturbation of pathways associated with Nerve growth factor (NGF) mediated signalling, the following chemical inhibitors were used – triciribine hydrate (**iAkt**, 5  $\mu$ M; Sigma T3830), Gö 6983 (**iPkc**, 0.5  $\mu$ M; Sigma G1918), and SCH772984 (**iErk**, 10  $\mu$ M; AbMole BioScience M2084).

All compounds and controls were tested as triplicate independent experiments. Importantly, to reduce inter-assay variations caused by evaporation of cell culture medium, cells were cultured only in wells B2-G11, the wells on the outer boundary of the plate were flooded with 300  $\mu$ l of HBSS over the time course of the entire assay.

# Immunofluorescence staining procedure<sup>16,17</sup>

48 hours after addition of test compounds and controls, the cells were fixed with 4:1 ratio of 20% formaldehyde and 5% sucrose for 30 min. After aspirating, the fixative was washed with HBSS (2 times), and the residual formaldehyde was treated with 0.1% NaBH<sub>4</sub> for 7 min and washed with HBSS (2 times). The cells were blocked and permeabilized with 5% goat serum in 0.3% Triton X-100 for 25 min. Cells were incubated with primary mouse anti-β-tubulin III antibody (Sigma T8578), 1:1000 diluted in antibody buffer (5% goat serum in 0.1% Triton X-100) overnight at 4°C. The primary antibody was aspirated and washed with HBSS (2 times). Neurites were stained with secondary antibody goat antimouse, Alexa Fluor Plus 488, Secondary Antibody (Invitrogen<sup>TM</sup> A28175) and the nuclei were stained with 0.5 µg/well of Hoechst 33342 (Invitrogen<sup>TM</sup> LSH3570) for 1h at 37°C. After the secondary antibody was aspirated and washed with HBSS (2 times), mounting solution (80% glycerol and 0.5% n-propyl gallate) was added.

#### Imaging acquisition parameters and data analyses

Images were acquired on a high content analysis system (Metaxpress XLS, Molecular Devices) with a Nikon  $10 \times$  Plan Fluor lens. 25 sites per well (covering the entire well) with 0 µm between images in X and Y direction were taken with a 100 ms exposure time for DAPI filter set and an 1800 ms exposure time for Alexa 488 filter set. A digital confocal mode was used to image neurites with five Z sections separated by 2 µm steps which were combined into a single stack for analysis. Proper image acquisition was confirmed in several wells to ensure that gain and exposure levels didn't result in images with saturated regions. The images were segmented and analyzed using Metaxpress' Neurite Outgrowth module, the parameters were set as shown:

| Segemented region | ed region Parameter                       |                    |
|-------------------|---|--------------------|
| Cell bodies       | Approximate maximum width                 | 25 μm              |
| Cell bodies       | Minimum area                              | 90 μm <sup>2</sup> |
| Nuclear stein     | Approximate minimum width                 | 4 µm               |
| Nuclear stan      | Approximate maximum width                 | 15 µm              |
| Outgrowth         | Maximum width                             | 4 μm               |
| Outgrowth         | Minimum cell growth to log as significant | 5 µm               |

For each well, the data generated for 25 images was added up to give the total number of cells and the total number of cells with significant outgrowth. An average cell body area was also calculated. Statistical analyses and graphing were done using GraphPad Prism version 9.2.0. p-values were determined by One-way ANOVA followed by Dunnett's multiple comparisons test or unpaired t-tests as mentioned in figures. Bar graphs have been plotted to show data as mean  $\pm$  standard deviation.



**Fig S1**. Image of *cis*-BG crystal at 10X magnification taken 24 h after addition of *cis*-BG in DMEM medium with 5% HS and 5% FBS. Similar results were seen when *cis*-BG was added to DMEM medium without any serum proteins.



**Fig S2**. Dose response curve of the potentiating effect of (–) *trans*-banglene when dosed along with 10 ng/mL of NGF. Curve simulated by GraphPad Prism using a dose-response curve model with variable slope (four parameters) with least squares fit.



Conc. (µM) of (-) t-BG

**Fig S3**. Fold change of neuritogenesis after treatment with increasing ( $\mu$ M) concentrations of (–) *trans*banglene for 48 h. % Neuritogenesis was calculated as a percentage of total number of cells that had neurites > 5  $\mu$ m. Fold change was calculated as % neuritogenesis (Compound) / % neuritogenesis (DMSO). p-value measured by unpaired t-test vs. DMSO \*\*\*p<0.001

| Treatments<br>compared                 | Figure<br>ref. | p-Value |
|--|----------------|---------|
| Vitamin E vs<br>NGF + 0.6% DMSO        | 4a             | 0.8440  |
| (-) 13 vs DMSO                         | 4c             | 0.3061  |
| (+) 13 vs DMSO                         | 4c             | 0.4437  |
| (+) <i>t</i> -BG vs<br>NGF + 0.6% DMSO | 4d             | 0.0788  |
| (-) 10 vs DMSO                         | 6              | 0.4035  |
| (±) 18 vs DMSO                         | 6              | 0.3440  |

Table S1. p-Values for key treatment comparisons which were not statistically significant

## **References:**

- 1. Kim, S. S.; Fang, Y.; Park, H. Synthesis and Anti-Inflammatory Activity of Phenylbutenoid Dimer Analogs. *Bull. Korean Chem. Soc.* **2015**, *36* (6), 1676–1680.
- 2. Fuchs, M.; Schober, M.; Pfeffer, J.; Kroutil, W.; Birner-Gruenberger, R.; Faber, K. Homoallylic Alcohols via a Chemo-Enzymatic One-Pot Oxidation-Allylation Cascade. *Adv. Synth. Catal.* **2011**, *353* (13), 2354–2358.
- 3. Huang, X. R.; Pan, X. H.; Lee, G. H.; Chen, C. C2-Symmetrical Bipyridyldiols as Promising Enantioselective Catalysts in Nozaki-Hiyama Allylation. *Adv. Synth. Catal.* **2011**, *353* (11–12), 1949–1954.
- 4. Fillion, E.; Dumas, A. M.; Hogg, S. A. Modular Synthesis of Tetrahydrofluorenones from 5-Alkylidene Meldrum's Acids. *J. Org. Chem.* **2006**, *71* (26), 9899–9902.
- 5. Davenport, E.; Fernandez, E. Transition-Metal-Free Synthesis of Vicinal Triborated Compounds and Selective Functionalisation of the Internal C–B Bond. *Chem. Commun.* **2018**, *54* (72), 10104–10107.
- Amatayakul, T.; Cannon, J. R.; Dampawan, P.; Dechatiwongse, T.; Giles, R. G. F.; Huntrakul, C.; Kusamran, K.; Mokkhasamit, M.; Raston, C. L.; Reutrakul, V.; White, A. H. Syntheses of Some Constituents of Zingiber Cassumunar. *Aust. J. Chem.* **1980**, *33* (4), 913–916.
- 7. Chu, J.; Suh, D.; Lee, G.; Han, A.; Chae, S.; Lee, H.; Seo, E.; Lim, H. Synthesis and Biological Activity of Optically Active Phenylbutenoid Dimers. *J. Nat. Prod.* **2011**, *74* (8), 1817–1821.
- 8. Diaz-Muñoz, G.; Isidorio, R. G.; Miranda, I. L.; de Souza Dias, G. N.; Diaz, M. A. N. A Concise and Efficient Synthesis of Tetrahydroquinoline Alkaloids Using the Phase Transfer Mediated Wittig Olefination Reaction. *Tetrahedron Lett.* **2017**, *58* (33), 3311–3315.
- 9. Paul Schmid; Matthias Maier; Hendrik Pfeiffer; Anja Belz; Lucas Henry; Alexandra Friedrich; Fabian Schönfeld; Katharina Edkins; Ulrich Schatzschneider. Catalyst-Free Room-Temperature IClick Reaction of Molybdenum( Ii ) and Tungsten( Ii ) Azide Complexes with Electron-Poor Alkynes: Structural Preferences and Kinetic Studies. *Dalt. Trans.* **2017**, *46* (39), 13386–13396.
- 10. Ngwendson, J. N.; Schultze, C. M.; Bollinger, J. W.; Banerjee, A. Effect of Base on Alkyltriphenylphosphonium Salts in Polar Aprotic Solvents. *Can. J. Chem.* **2011**, *86* (7), 668–675.
- Mohideen, M.; Zulkepli, S.; Nik-Salleh, N. S.; Zulkefeli, M.; Weber, J. F. F. A.; Rahman, A. F. M. M. Design, Synthesis, in Vitro Cytotoxicity Evaluation and Structure-Activity Relationship of Goniothalamin Analogs. *Arch. Pharm. Res.* 2013, *36* (7), 812–831.
- 12. Moghaddam, F. M.; Farimani, M. M. A Simple and Efficient Total Synthesis of (±)-Danshexinkun A, a Bioactive Diterpenoid from Salvia Miltiorrhiza. *Tetrahedron Lett.* **2010**, *51* (3), 540–542.
- Montgomery, T. P.; Grandner, J. M.; Houk, K. N.; Grubbs, R. H. Synthesis and Evaluation of Sterically Demanding Ruthenium Dithiolate Catalysts for Stereoretentive Olefin Metathesis. *Organometallics* 2017, *36* (20), 3940–3953.
- 14. Díaz, E.; Reyes, E.; Uria, U.; Carrillo, L.; Tejero, T.; Merino, P.; Vicario, J. L. Carboxylates as Nucleophiles in the Enantioselective Ring-Opening of Formylcyclopropanes under Iminium Ion Catalysis. *Chem. A Eur. J.* **2018**, *24* (35), 8764–8768.
- Matsui, N.; Kido, Y.; Okada, H.; Kubo, M.; Nakai, M.; Fukuishi, N.; Fukuyama, Y.; Akagi, M. Phenylbutenoid Dimers Isolated from Zingiber Purpureum Exert Neurotrophic Effects on Cultured Neurons and Enhance Hippocampal Neurogenesis in Olfactory Bulbectomized Mice. *Neurosci. Lett.* 2012, *513* (1), 72–77.
- Radio, N. M.; Breier, J. M.; Shafer, T. J.; Mundy, W. R. Assessment of Chemical Effects on Neurite Outgrowth in PC12 Cells Using High Content Screening. *Toxicol. Sci.* 2008, 105 (1), 106– 118.
- 17. Harrill, J. A.; Mundy, W. R. *Quantitative Assessment of Neurite Outgrowth in PC12 Cells*; Humana Press, Totowa, NJ, **2011**; Vol. 758.



#### Figure S4: <sup>1</sup>H NMR spectrum of compound 2a (CDCl<sub>3</sub>, 400 MHz)





# Figure S6: <sup>1</sup>H NMR spectrum of compound **2b** (CDCl<sub>3</sub>, 400 MHz)



#### Figure S7: <sup>13</sup>C NMR spectrum of compound **2b** (CDCl<sub>3</sub>, 176 MHz)



# Figure S8: <sup>1</sup>H NMR spectrum of compound 2c (CDCl<sub>3</sub>, 700 MHz)



#### Figure S9: <sup>13</sup>C NMR spectrum of compound 2c (CDCl<sub>3</sub>, 176 MHz)

Figure S10: <sup>1</sup>H NMR spectrum of compound 2d (CDCl<sub>3</sub>, 600 MHz)



Figure S11: <sup>13</sup>C NMR spectrum of compound 2d (CDCl<sub>3</sub>, 126 MHz)



# Figure S12: <sup>1</sup>H NMR spectrum of compound 3a (CDCl<sub>3</sub>, 500 MHz)



### Figure S13: <sup>13</sup>C NMR spectrum of compound 3a (CDCl<sub>3</sub>, 126 MHz)



## Figure S14: <sup>1</sup>H NMR spectrum of compound 3c (CDCl<sub>3</sub>, 500 MHz)

499.787 MHz H1 1D in cdcl3 (ref. to CDCl3 @ 7.26 ppm) temp 27.7 C -> actual temp = 27.0 C, colddual

но ОМе



Figure S15: <sup>13</sup>C NMR spectrum of compound 3c (CDCl<sub>3</sub>, 126 MHz)

125.685 MHz C13{H1} 1D in cdcl3 (ref. to CDCl3 @ 77.06 ppm) temp 27.7 C -> actual temp = 27.0 C, colddual

но ОМе



+S55 10 120 110 30 20 240 230 220 210 200 190 180 170 160 150 140 130 100 90 80 70 60 50 40 -10 0 f1 (ppm)

#### **Figure S16:** <sup>1</sup>H NMR spectrum of compound *c*–**BG** (CDCl<sub>3</sub>, 700 MHz)



# Figure S17: <sup>1</sup>H NMR magnified spectrum of compound *c*–BG (CDCl<sub>3</sub>, 700 MHz)



| Recorded on: v700, Nov 1 2019 | Sweep Width(Hz): 8389.26  | Acquisiton Time(s): 5   | Relaxation Delay(s): 0.1 |
|-------------------------------|---------------------------|-------------------------|--------------------------|
| Pulse Sequence: PRESAT        | Digital Res.(Hz/pt): 0.13 | Hz per mm(Hz/mm): 29.16 | Completed Scans 8        |
|                               |                           |                         |                          |





### Figure S18: <sup>13</sup>C NMR spectrum of compound *c*–BG (CDCl<sub>3</sub>, 176 MHz)

## Figure S19: <sup>1</sup>H NMR spectrum of compound *t*–BG (CDCl<sub>3</sub>, 700 MHz)



# Figure S20: <sup>1</sup>H NMR magnified spectrum of compound *t*–BG (CDCl<sub>3</sub>, 700 MHz)



| Recorded on: v700, Nov 1 2019 | Sweep Width(Hz): 8389.26  | Acquisiton Time(s): 5   | Relaxation Delay(s): 0.1 |
|-------------------------------|---------------------------|-------------------------|--------------------------|
| Pulse Sequence: PRESAT        | Digital Res.(Hz/pt): 0.13 | Hz per mm(Hz/mm): 29.16 | Completed Scans 8        |
|                               |                           |                         |                          |





# Figure S21: <sup>1</sup>H NMR magnified spectrum of compound *t*–BG (CDCl<sub>3</sub>, 700 MHz)





# Figure S22: <sup>13</sup>C NMR spectrum of compound *t*–BG (CDCl<sub>3</sub>, 176 MHz)



#### Recorded on: u500, Sep 1 2020 Sweep Width(Hz): 6009.62 Acquisiton Time(s): 5 Relaxation Delay(s): 0.1 Pulse Sequence: PRESAT Digital Res.(Hz/pt): 0.09 Hz per mm(Hz/mm): 20.82 Completed Scans 8 MeO OMe 9.498 7.260 6.809 6.719 5.988 5.973 3.909 2.158 6.793 6.772 6.768 6.756 6.752 6.722 5.997 5.993 5.983 5.970 5.964 5.836 5.832 5.823 5.819 5.816 5.812 5.803 3.933 3.928 3.925 3.917 3.913 3.844 3.834 2.746 2.733 2.722 2.717 2.276 2.271 2.174 2.168 2.153 1.873 1.862 1.850 1.846 0.069 9.502 5.977 5.827 5.807 3.921 3.851 2.267 1.887 1.877 7 3 9 8 6 5 4 2 1 ppm1.00 ± ( 1.00 ± 1.06 6.42 ΨΨ. 1.00 -[ **98 −** 0.98 Υ $1.01 \\ 1.01 \\ 1.01$ 2.24 2.07 S63

# Figure S23: <sup>1</sup>H NMR spectrum of compound 5a (CDCl<sub>3</sub>, 500 MHz)

# Figure S24: <sup>1</sup>H NMR magnified spectrum of compound 5a (CDCl<sub>3</sub>, 500 MHz)



| Recorded on: <b>u500, Sep 1 2020</b> | Sweep Width(Hz): 6009.62  | Acquisiton Time(s): 5   | Relaxation Delay(s): 0.1 |
|--------------------------------------|---------------------------|-------------------------|--------------------------|
| Pulse Sequence: <b>PRESAT</b>        | Digital Res.(Hz/pt): 0.09 | Hz per mm(Hz/mm): 20.82 | Completed Scans 8        |





# Figure S25: <sup>13</sup>C NMR spectrum of compound 5a (CDCl<sub>3</sub>, 126 MHz)



# Figure S26: <sup>1</sup>H NMR spectrum of compound 5b (CDCl<sub>3</sub>, 500 MHz)



## Figure S27: <sup>13</sup>C NMR spectrum of compound 5b (CDCl<sub>3</sub>, 176 MHz)

# Figure S28: <sup>1</sup>H NMR spectrum of compound 5c (CDCl<sub>3</sub>, 700 MHz)



# Figure S29: <sup>13</sup>C NMR spectrum of compound 5c (CDCl<sub>3</sub>, 176 MHz)



#### Figure S30: <sup>1</sup>H NMR spectrum of compound 5d (CDCl<sub>3</sub>, 500 MHz)

499.787 MHz H1 1D in cdcl3 (ref. to CDCl3 @ 7.26 ppm) temp 27.7 C -> actual temp = 27.0 C, colddual probe



#### Figure S31: <sup>13</sup>C NMR spectrum of compound 5d (CDCl<sub>3</sub>, 126 MHz)

125.685 MHz C13{H1} 1D in cdcl3 (ref. to CDCl3 @ 77.06 ppm) temp 27.7 C -> actual temp = 27.0 C, colddual probe





# Figure S32: <sup>1</sup>H NMR spectrum of compound 6a (CDCl<sub>3</sub>, 500 MHz)
## Figure S33: <sup>1</sup>H NMR magnified spectrum of compound 6a (CDCl<sub>3</sub>, 500 MHz)



| Recorded on: u500, Sep 1 2020<br>Pulse Sequence: PRESAT |
|---|
|---|





## Figure S34: <sup>13</sup>C NMR spectrum of compound 6a (CDCl<sub>3</sub>, 126 MHz)

### Figure S35: <sup>1</sup>H NMR spectrum of compound 6b (CDCl<sub>3</sub>, 500 MHz)



| 203.811   |   |   | 100<br>201<br>201                             | <br>   | 77.314   | 76.806   | 55.256<br>\53.867                     | 41.424               | 23.447<br>20.924   |
|---|---|---|---|--|--|--|---------------------------------------|----------------------|--|
|   |   |   |   |  |  |  |                                       |                      |  |
|   |   |   |   |  |  |  |                                       |                      |  |
|   |   |   |   |  |  |  |                                       |                      |  |
| llander die kandelig verbeiten der bestelligen der bestelligen der bestelligen der bestelligen der bestelligt e<br>Premissionen einer stenste der premission premission operationen president premission operation operation operat | hala an | ulikustani)<br>Alikustani)<br>Alikustani) | adda a baan a baadd y<br>we gan gan gan gan g | had a land a start of the start | unalla attisticad dada<br>prana pri production | Holy Labor of<br>Holy Labor of<br>Holy Public Property | kin faile to the failed at the second | ling of a set of the | hu (kala san pilipi pil |

# **Figure S36:** <sup>13</sup>C NMR spectrum of compound **6b** (CDCl<sub>3</sub>, 126 MHz)

## Figure S37: <sup>1</sup>H NMR spectrum of compound 6c (CDCl<sub>3</sub>, 500 MHz)



## Figure S38: <sup>13</sup>C NMR spectrum of compound 6c (CDCl<sub>3</sub>, 126 MHz)



### Figure S39: <sup>1</sup>H NMR spectrum of compound 7a (CDCl<sub>3</sub>, 400 MHz)



#### Figure S40: <sup>13</sup>C NMR spectrum of compound 7a (CDCl<sub>3</sub>, 176 MHz)



## **Figure S41:** <sup>31</sup>P{<sup>1</sup>H} NMR spectrum of compound **7a** (CDCl<sub>3</sub>, 162 MHz)



| Recorded on: mr400, Jul 25 2020 | Sweep Width(Hz): 11363.6  | Acquisiton Time(s): 1          | Relaxation Delay(s): 0.1 |
|---------------------------------|---------------------------|--------------------------------|--------------------------|
| Pulse Sequence: s2pul           | Digital Res.(Hz/pt): 0.09 | Hz per mm(Hz/mm): <b>47.35</b> | Completed Scans 64       |

22.524



.

viyedaraan in padalah padalaha

#### Figure S42: <sup>1</sup>H NMR spectrum of compound 7b (CDCl<sub>3</sub>, 400 MHz)



## Figure S43: <sup>13</sup>C NMR spectrum of compound 7b (CDCl<sub>3</sub>, 176 MHz)



# **Figure S44:** <sup>31</sup>P{<sup>1</sup>H} NMR spectrum of compound **7b** (CDCl<sub>3</sub>, 162 MHz)



| Recorded on: mr400, Jul 25 2020 | Sweep Width(Hz):     | 11363.6 | Acquisiton Time(s): 1   | Relaxation Delay(s): 0.1 |
|---------------------------------|----------------------|---------|-------------------------|--------------------------|
| Pulse Sequence: s2pul           | Digital Res.(Hz/pt): | 0.09    | Hz per mm(Hz/mm): 47.35 | Completed Scans 64       |

23.201



#### OMe Recorded on: mr400, Jul 25 2020 Sweep Width(Hz): 4807.69 Acquisiton Time(s): 5 Relaxation Delay(s): 0.1 Pulse Sequence: PRESAT Digital Res.(Hz/pt): 0.07 Hz per mm(Hz/mm): 16.67 Completed Scans 16 ⊕ ⊖ .PPh₃Br 7.783 7.768 7.764 7.761 7.750 7.750 7.732 7.729 7.654 7.645 7.260 7.018 6.813 5.412 1.608 7.634 1.627 7.615 7.611 7.606 3.549 Т 9 8 7 6 5 3 2 4 1 ppm8.84 <del>|</del> 5.94 <del>|</del> 2.00 -[ 0.57 -[ 3.01 -[ 1.02 0.98 1.00 S85

## Figure S45: <sup>1</sup>H NMR spectrum of compound 7c (CDCl<sub>3</sub>, 400 MHz)

### Figure S46: <sup>13</sup>C NMR spectrum of compound 7c (CDCl<sub>3</sub>, 176 MHz)





# **Figure S47:** <sup>31</sup>P{<sup>1</sup>H} NMR spectrum of compound **7c** (CDCl<sub>3</sub>, 162 MHz)



| Recorded on: mr400, Jul 25 2020 | Sweep Width(Hz): 11363.6  | Acquisiton Time(s): 1   | Relaxation Delay(s): 0.1 |
|---------------------------------|---------------------------|-------------------------|--------------------------|
| Pulse Sequence: s2pul           | Digital Res.(Hz/pt): 0.09 | Hz per mm(Hz/mm): 47.35 | Completed Scans 64       |

23.226



## Figure S48: <sup>1</sup>H NMR spectrum of compound 7d (CDCl<sub>3</sub>, 400 MHz)



#### Figure S49: <sup>13</sup>C NMR spectrum of compound 7d (CDCl<sub>3</sub>, 176 MHz)



## Figure S50: <sup>31</sup>P{<sup>1</sup>H} NMR spectrum of compound 7d (CDCl<sub>3</sub>, 162 MHz)







### Figure S51: <sup>1</sup>H NMR spectrum of compound 7e (CDCl<sub>3</sub>, 400 MHz)



## ⊕ ⊖ PPh₃Br Recorded on: v700, Jul 25 2020 Sweep Width(Hz): 36764.7 Acquisiton Time(s): 1 Relaxation Delay(s): 1 Pulse Sequence: s2pul Digital Res.(Hz/pt): 0.28 Hz per mm(Hz/mm): 139.31 Completed Scans 256 -135.070 -135.054 -134.412 -134.356130.186 118.247 117.764 28.664 <del>-130</del>.981 130.257 128.780 126.752 77.242 76.878 19.669 990 **ppm** S92 180 160 140 120 100 80 20 60 40

## Figure S52: <sup>13</sup>C NMR spectrum of compound 7e (CDCl<sub>3</sub>, 176 MHz)

# **Figure S53:** <sup>31</sup>P{<sup>1</sup>H} NMR spectrum of compound **7e** (CDCl<sub>3</sub>, 162 MHz)



| Recorded on: mr400, Jul 25 2020 | Sweep Width(Hz): 11363.6  | Acquisiton Time(s): 1   | Relaxation Delay(s): 0.1 |
|---------------------------------|---------------------------|-------------------------|--------------------------|
| Pulse Sequence: s2pul           | Digital Res.(Hz/pt): 0.09 | Hz per mm(Hz/mm): 47.35 | Completed Scans 72       |

-22.191



### Figure S54: <sup>1</sup>H NMR spectrum of compound 7f (CDCl<sub>3</sub>, 500 MHz)



## Figure S55: <sup>13</sup>C NMR spectrum of compound 7f (CDCl<sub>3</sub>, 126 MHz)



### Figure S56: <sup>1</sup>H NMR spectrum of compound 8 (CDCl<sub>3</sub>, 500 MHz)



## Figure S57: <sup>1</sup>H NMR magnified spectrum of compound 8 (CDCl<sub>3</sub>, 500 MHz)



| Recorded on: <b>u500, Aug 1</b> | <b>2020</b> Sweep Width(Hz): | 6009.62 | Acquisiton Time(s): | 5     | Relaxation Delay(s): 0.1 |
|---------------------------------|------------------------------|---------|---------------------|-------|--------------------------|
| Pulse Sequence: <b>PRESAT</b>   | Digital Res.(Hz/pt):         | 0.09    | Hz per mm(Hz/mm)    | 20.82 | Completed Scans 8        |



### Figure S58: <sup>13</sup>C NMR spectrum of compound 8 (CDCl<sub>3</sub>, 126 MHz)



180



### Figure S59: <sup>1</sup>H NMR spectrum of compound 9 (CDCl<sub>3</sub>, 700 MHz)



### Figure S60: <sup>13</sup>C NMR spectrum of compound 9 (CDCl<sub>3</sub>, 176 MHz)



### Figure S61: <sup>1</sup>H NMR spectrum of compound 10 (CDCl<sub>3</sub>, 700 MHz)



## Figure S62: <sup>13</sup>C NMR spectrum of compound 10 (CDCl<sub>3</sub>, 176 MHz)



### Figure S63: <sup>1</sup>H NMR spectrum of compound 11 (CDCl<sub>3</sub>, 700 MHz)



## Figure S64: <sup>13</sup>C NMR spectrum of compound 11 (CDCl<sub>3</sub>, 176 MHz)



### Figure S65: <sup>1</sup>H NMR spectrum of compound 12 (CDCl<sub>3</sub>, 700 MHz)



## Figure S66: <sup>13</sup>C NMR spectrum of compound **12** (CDCl<sub>3</sub>, 176 MHz)



### Figure S67: <sup>1</sup>H NMR spectrum of compound 13 (CDCl<sub>3</sub>, 700 MHz)



## Figure S68: <sup>1</sup>H NMR magnified spectrum of compound 13 (CDCl<sub>3</sub>, 700 MHz)


# Figure S69: <sup>1</sup>H NMR magnified spectrum of compound 13 (CDCl<sub>3</sub>, 700 MHz)



#### Figure S70: <sup>13</sup>C NMR spectrum of compound 13 (CDCl<sub>3</sub>, 176 MHz)



#### .OMe Recorded on: u500, Aug 15 2020 Sweep Width(Hz): 6009.62 Acquisiton Time(s): 5 Relaxation Delay(s): 0.1 Pulse Sequence: PRESAT Digital Res.(Hz/pt): 0.09 Hz per mm(Hz/mm): 20.82 Completed Scans 8 MeO 7.112 7.096 7.081 6.733 6.697 6.685 6.654 6.650 6.638 6.543 6.458 6.419 6.293 5.648 3.833 3.723 3.717 2.170 2.166 2.160 ĠМе 7.260 6.717 6.701 6.680 6.634 6.539 6.443 6.422 6.316 5.652 5.632 5.565 5.563 5.542 1.542 1.258 0.073 5.586 9 8 7 5 4 3 2 1 ppm6 1.00 -{ ₩4 66.0 ΥY 0.99 -0.98 -Her under Ψ 11 Т 1.00 3.04 5.89 1.21 66.0 2.14 1.04

S111

#### Figure S71: <sup>1</sup>H NMR spectrum of compound 14 (CDCl<sub>3</sub>, 500 MHz)

# Figure S72: <sup>13</sup>C NMR spectrum of compound 14 (CDCl<sub>3</sub>, 126 MHz)



#### Figure S73: <sup>1</sup>H NMR spectrum of compound 15 (CDCl<sub>3</sub>, 500 MHz)



# Figure S74: <sup>13</sup>C NMR spectrum of compound 15 (CDCl<sub>3</sub>, 126 MHz)



#### Figure S75: <sup>1</sup>H NMR spectrum of compound 16 (CDCl<sub>3</sub>, 700 MHz)



#### Figure S76: <sup>13</sup>C NMR spectrum of compound 16 (CDCl<sub>3</sub>, 176 MHz)



#### Figure S77: <sup>1</sup>H NMR spectrum of compound 17 (CDCl<sub>3</sub>, 700 MHz)



# Figure S78: <sup>1</sup>H NMR magnified spectrum of compound **17** (CDCl<sub>3</sub>, 700 MHz)





# Figure S79: <sup>1</sup>H NMR magnified spectrum of compound 17 (CDCl<sub>3</sub>, 700 MHz)





#### Figure S80: <sup>13</sup>C NMR spectrum of compound 17 (CDCl<sub>3</sub>, 176 MHz)



#### Recorded on: u500, Aug 14 2020 Sweep Width(Hz): 6009.62 Acquisiton Time(s): 5 Relaxation Delay(s): 0.1 .OMe Pulse Sequence: PRESAT Digital Res.(Hz/pt): 0.09 Hz per mm(Hz/mm): 20.82 Completed Scans 8 OMe ÓМе -7.260 -7.111 -7.107 -7.098 -7.093 -6.826 6.815 6.809 6.794 6.089 6.045 6.030 3.877 3.857 3.780 1.535 6.822 6.819 6.790 6.776 6.760 1.258 0.073 Т 9 8 7 6 5 4 3 2 1 ppm1.01 1.01 f 1.97 f 6.16 ∱ 3.05 ∱ 1.99 -0.08 1.00 1.00 1.00 -{ Ψ 1.01 -Ч 1.09 5.02

S121

#### Figure S81: <sup>1</sup>H NMR spectrum of compound 18 (CDCl<sub>3</sub>, 500 MHz)

# Figure S82: <sup>13</sup>C NMR spectrum of compound 18 (CDCl<sub>3</sub>, 126 MHz)



#### Figure S83: <sup>1</sup>H NMR spectrum of compound 19 (CDCl<sub>3</sub>, 500 MHz)



Figure S84: <sup>13</sup>C NMR spectrum of compound 19 (CDCl<sub>3</sub>, 126 MHz)



#### Figure S85: <sup>1</sup>H NMR spectrum of compound 20 (CDCl<sub>3</sub>, 700 MHz)



# Figure S86: <sup>1</sup>H NMR magnified spectrum of compound 20 (CDCl<sub>3</sub>, 700 MHz)



| Recorded on: v700, Aug 14 2020 | Sweep Width(Hz): 8389.26  | Acquisiton Time(s): 5   | Relaxation Delay(s): 0.1 |
|--------------------------------|---------------------------|-------------------------|--------------------------|
| Pulse Sequence: PRESAT         | Digital Res.(Hz/pt): 0.13 | Hz per mm(Hz/mm): 29.16 | Completed Scans 8        |
|                                |                           |                         |                          |



# Figure S87: <sup>1</sup>H NMR magnified spectrum of compound 20 (CDCl<sub>3</sub>, 700 MHz)



| Recorded on: v700, Aug 14 2020 | Sweep Width(Hz): 8389.26  | Acquisiton Time(s): <b>5</b>   | Relaxation Delay(s): 0.1 |
|--------------------------------|---------------------------|--------------------------------|--------------------------|
| Pulse Sequence: PRESAT         | Digital Res.(Hz/pt): 0.13 | Hz per mm(Hz/mm): <b>29.16</b> | Completed Scans 8        |
|                                |                           |                                |                          |



# Figure S88: <sup>13</sup>C NMR spectrum of compound 20 (CDCl<sub>3</sub>, 176 MHz)



#### Figure S89: <sup>1</sup>H NMR spectrum of compound 21 (CDCl<sub>3</sub>, 700 MHz)



# Figure S90: <sup>1</sup>H NMR magnified spectrum of compound 21 (CDCl<sub>3</sub>, 700 MHz)



| Pulse Sequence:         PRESAT         Digital Res.(Hz/pt):         0.13         Hz per mm(Hz/mm):         29.16         Completed Scans         8 | Recorded on: v700, Aug 14 2020 | Sweep Width(Hz): 8389.26  | Acquisiton Time(s): 5   | Relaxation Delay(s): 0.1 |
|--|--------------------------------|---------------------------|-------------------------|--------------------------|
|  | Pulse Sequence: PRESAT         | Digital Res.(Hz/pt): 0.13 | Hz per mm(Hz/mm): 29.16 | Completed Scans 8        |



# Figure S91: <sup>1</sup>H NMR magnified spectrum of compound 21 (CDCl<sub>3</sub>, 700 MHz)



| Recorded on: v700, Aug 14 2020 | Sweep Width(Hz):     | 8389.26 | Acquisiton Time(s): 5   | Relaxation Delay(s): 0.1 |
|--------------------------------|----------------------|---------|-------------------------|--------------------------|
| Pulse Sequence: PRESAT         | Digital Res.(Hz/pt): | 0.13    | Hz per mm(Hz/mm): 29.16 | Completed Scans 8        |



# Figure S92: <sup>13</sup>C NMR spectrum of compound 21 (CDCl<sub>3</sub>, 176 MHz)



#### Figure S93: <sup>1</sup>H NMR spectrum of compound 22 (CDCl<sub>3</sub>, 700 MHz)



# Figure S94: <sup>1</sup>H NMR magnified spectrum of compound 22 (CDCl<sub>3</sub>, 700 MHz)



| Recorded on: v700, Aug 13 2020 | Sweep Width(Hz): 8389.26  | Acquisiton Time(s): 5   | Relaxation Delay(s): 0.1 |
|--------------------------------|---------------------------|-------------------------|--------------------------|
| Pulse Sequence: PRESAT         | Digital Res.(Hz/pt): 0.13 | Hz per mm(Hz/mm): 29.16 | Completed Scans 8        |
|                                |                           |                         |                          |



# Figure S95: <sup>1</sup>H NMR magnified spectrum of compound 22 (CDCl<sub>3</sub>, 700 MHz)



# Figure S96: <sup>13</sup>C NMR spectrum of compound 22 (CDCl<sub>3</sub>, 176 MHz)



#### Figure S97: <sup>1</sup>H NMR spectrum of compound 23 (CDCl<sub>3</sub>, 700 MHz)



# Figure S98: <sup>1</sup>H NMR spectrum of compound 23 (CDCl<sub>3</sub>, 700 MHz)



# Figure S99: <sup>1</sup>H NMR spectrum of compound 23 (CDCl<sub>3</sub>, 700 MHz)



| Recorded on:         v700, Aug 14 2020         Sweep Width(Hz):         8389.26         Acquisiton Time(s):         5         Relaxation Dependence           Pulse Sequence:         PRESAT         Digital Res.(Hz/pt):         0.13         Hz per mm(Hz/mm):         29.16         Completed Set | lay(s): <b>0.1</b><br>ans <b>8</b> |
|--|------------------------------------|
|--|------------------------------------|



# Figure S100: <sup>13</sup>C NMR spectrum of compound 23 (CDCl<sub>3</sub>, 176 MHz)





#### Figure S102: <sup>13</sup>C NMR spectrum of compound 24 (CDCl<sub>3</sub>, 176 MHz)



Figure S103: <sup>1</sup>H NMR spectrum of compound 25 (CDCl<sub>3</sub>, 700 MHz)



#### Figure S104: <sup>13</sup>C NMR spectrum of compound 25 (CDCl<sub>3</sub>, 176 MHz)

.OMe

ОМе

MeO

ÓМе

| 2019.01.24.v7_zhk_hydrogenated_cis_PB0_tb659_163382C13_1D   | 25   | 63<br>22<br>75 | <u></u><br><u> </u> <u> </u> | Ω    | 0    | 999990                       |      |
|---|------|----------------|---|------|------|------------------------------|------|
| Zain, zhk_hydrogenated_cis_PBD                              | 19.  | 11110          | 5 5 5 5<br>6 7 8  | 15.9 | 39.3 | 33.6<br>29.6<br>27.2<br>26.5 | 20.5 |
| 175.971 MHz C13{H1} 1D in cdcl3 (ref. to CDC13 @ 77.06 ppm) | - 72 |                |   | Ì    | Ĩ    |                              | Î    |
| temp 27.5 C -> actual temp = 27.0 C, coldid probe           | 11   | חור            | т   |      | 1.1  | 1 1 117                      | 1    |



S144 10 f1 (ppm)
Figure S105: <sup>1</sup>H NMR spectrum of compound 26 (CDCl<sub>3</sub>, 700 MHz)



175.971 MHz C13{H1} 1D in cdcl3 (ref. to CDCl3 @ 77.06 ppm) temp 27.5 C -> actual temp = 27.0 C, coldid probe







